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Patient harms, or adverse events (AEs) which is the term used in this PhD thesis, is a major 
global health problem. They cause suffering for patients, are stressful for involved health 
personnel and costly for the healthcare services. Acknowledging that such events happen is 
necessary in order to improve patient safety. The Global Trigger Tool (GTT) has been used to 
track AEs over time in Norwegian hospitals from 2011. The method involves a review team 
who screens randomly selected patient records for predefined triggers (situations) that could 
indicate that an AE has happened. A trigger can be use of blood products, an infection, abrupt 
medication stop or a readmission. If one or more of such triggers are present, a more in-depth 
review is performed to decide if the trigger represent an AE. The GTT method has 
demonstrated high sensitivity in comparison to other methods, such as voluntary incident 
reporting, quality indicators from administrative data and claims for compensation. However, 
the GTT method is criticized because of the sampling strategy, low agreement between 
review teams and that the method is time consuming to perform. 
 
This PhD evaluated if increasing the number of records to be reviewed (Paper I), changes of 
reviewers (Paper II) and automatically identification of triggers (Paper III) improved the 
reliability and validity of the GTT method.  
 
The results showed that increasing the number of reviewed records seven times increased the 
rate of identified AEs by 45 %. The confidence interval was narrower in a large sample 
compared to a small sample. Review teams with at least one identical reviewer demonstrated 
substantial agreement compared to moderate agreement between review teams with no 
identical reviewers. Automatic identification of triggers saved review time and use of this tool 
identified equal rates of AEs comparable to the original GTT method with manual trigger 
identification.  
 
In conclusion, these studies showed that if the number of reviewed records is increased, at 
least one reviewer is consistent and automatic trigger identification is used, the method’s 







SAMMENDRAG (summary in Norwegian) 
Pasientskader, eller uønskede hendelser som er begrepet brukt i denne ph.d. avhandlingen, er 
et betydelig globalt helseproblem. De forårsaker lidelse hos pasienter, er belastende for 
involvert helsepersonell og kostbare for helsevesenet. Anerkjenning av at slike hendelser skjer 
er nødvendig for å kunne bedre pasientsikkerheten. Metoden Global Trigger Tool (GTT) ble 
derfor innført ved alle norske sykehus fra 2011 med det formål å følge antall uønskede 
hendelser over tid. Metoden går ut på at ett granskningsteam gransker et tilfeldig utvalg av 
pasientopphold etter forhåndsdefinerte triggere (situasjoner) som kan indikere at en uønsket 
hendelse kan ha skjedd. En trigger kan være bruk av blodprodukter, en infeksjon, plutselig 
seponering av ett medikament eller en reinnleggelse. Hvis en eller flere slike triggere er 
tilstede, gjøres en mer grundig gjennomgang for å finne ut om triggeren er assosiert med en 
uønsket hendelse. GTT metoden har høy sensitivitet i forhold til andre metoder som 
avviksmeldinger, kvalitetsindikatorer basert på administrative data og klagesaker. Imidlertid 
er GTT metoden kritisert fordi den baseres på granskning av små utvalg av pasientopphold, 
har dårlig samsvar mellom forskjellige granskningsteam og at metoden er tidskrevende å 
gjennomføre. 
 
Denne doktorgradsavhandlingen evaluerte om økning av antall pasientopphold som granskes 
(Artikkel I), utskifting av granskere (Artikkel II) og automatisk identifisering av triggere 
(Artikkel III) bedret metodens reliabilitet (pålitelighet) og validitet (gyldighet). 
 
Resultatene viste at ved å øke utvalget av granskede pasientopphold sju ganger, økte raten av 
antall identifiserte uønskede hendelser med 45 %. Konfidensintervallet var smalere i et stort 
utvalg sammenlignet med ett lite utvalg. Granskingsteam som hadde minst en lik gransker 
viste godt samsvar sammenlignet med team som ikke hadde noen like granskere. Automatisk 
identifisering av triggere sparer granskningstid, og bruk av dette verktøyet identifiserte 
samme rate av uønskede hendelser som ved bruk av den original GTT metoden med manuell 
trigger identifisering. Oppsummert viser studien at hvis man gransker større utvalg av 
pasientopphold, beholder minst en gransker stabil i granskingsteamet og bruker automatisk 
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“To err is human; to cover up is unforgivable; and to fail to learn is inexcusable.” 





Patient harms, or adverse events due to medical care, is a major global health problem as they 
cause suffering for patients and are stressful for involved healthcare professionals [1]. In 
addition they are costly for the healthcare services [2]. Acknowledging that such events 
happen and measuring them, are necessary for improving health care and increasing patient 
safety [3]. 
 
The common methods (i.e.; incident reporting, quality indicators, processes for dealing with 
complaints and mortality & morbidity conferences) of reporting and analysing adverse events 
are unfortunately inappropriate for measuring adverse events mostly due to reporting bias [3]. 
These systems depend on either the patients, their relatives or health personnel voluntary 
reporting the adverse events.  
 
Review of patient records for specific triggers (situations) such as use of blood products, 
abrupt stop in medication or readmissions, is an alternative method to identify and measure 
adverse events. Such method has demonstrated high sensitivity in comparison to the referred 
methods above [4]. The widely used method for identifying and measuring adverse events is 
the Global Trigger Tool (GTT), developed by the Institute of Healthcare Improvement (IHI) 
in Cambridge, USA [5]. Frequent use of the GTT method has demonstrated that adverse 
events are far more common than first assumed [6], [7]. Estimates show that adverse events 
happen as frequent as up to 30 % of the inpatient population [6]. 
 
However, the GTT has some practical disadvantages. It is rather resource intensive due to 
time and personnel required. The sampling approach, reviewing only small samples of 
records, together with frequent replacement of reviewers question the reliability and validity 







events by increasing the number of reviewed records and changing the reviewers. Use of 
automatic identification of triggers was also evaluated. As the GTT is used in all Norwegian 
hospitals the aim of the thesis was to make the GTT method a more efficient, valid and 







1.2 Adverse events 
1.2.1 Definitions 
Several different terms describing adverse outcomes of medical care are used (table 1). 
Inconsistent use of terms, which appear both in the literature and in the clinical settings, 
complicates the understanding of adverse outcomes due to medical care [10].   
 
Table 1 Terms describing adverse outcomes 
Term Definition Pros Cons 
Errors a failure to carry out a planned action as 
intended or application of an incorrect 
plan [11] 
Identify failures Promotes blaming 
Inhibit system 
approach 
Injuries damage to tissues caused by an agent or 
event [11] 
 Only severe events 
Patient harms an outcome that negatively affects a 
patient’s health and/or quality of life 
[12] 
Already in use Used differently 
whatever 
considered a 
severe event, a 
claim or adverse 
outcomes 
Adverse events unintended physical injury resulting 
from or contributed to by medical care 
that requires additional monitoring, 
treatment or hospitalisation, or that 
results in death [5] 
System approach 







Complications an unfavourable evolution or 
consequence of a disease, a health 
condition or a therapy [13] 
Already in use Acceptance of the 




harm arising from or associated with 
plans or actions taken during the 
provision of healthcare, rather than from 
an underlying disease or injury [10] 
No doubt that the 
harm is due to the 
healthcare given 
Too complicated 








Identification and measurement of adverse outcomes from medical care depend on a common 
definition of what constitutes this term, in order to increase the understanding of such events  
[14]. Consistent use of patient safety terms is also necessary for making comparison between 
facilities possible and to track the trends over time [10]. A group, initiated from the World 
Health Organisation (WHO), agreed upon 48 concepts aiming for that this agreement could 
pave the way for a common understanding of the concepts of patient safety [10]. Common 
definitions would probably increase the focus on these events promoting implementation of 
interventions to prevent them. However, deciding the contribution of medical intervention in 
regard to the underlying disease to an event, is often difficult. For example; an unplanned unit 
of blood is infused to an anaemic patient after an operation. It is not always obvious if the 
anaemia is due to the medical condition or due to the operation. The type of medical condition 
is important to consider when deciding if the event was due to the condition. A definition 
including criteria for defining it as an adverse outcome due to medical care, would make it 
easier to decide. A discussion concerning when to use and not to use the different terms 
follow, as well as their suitability as measures of adverse outcomes. 
 
Using the term error for the adverse outcome often brings up the question of whom is to 
blame. The blame perspective makes the culture for analysis the event difficult. A “just” 
culture promotes a system approach, rather than blaming and shaming on individuals [3], 
[15], [16]. Most errors are committed by good hardworking people and identifying who’s to 
blame is a distraction. It is far more productive to identify the situations that caused the error 
and implementing systems that will prevent them from happening again [17]. However, the 
fact that all errors do not result in adverse outcomes and all adverse outcomes are not 
necessary a result of errors, makes measuring errors not suitable as a measure [18].  
 
The terms injury or harm do not distinguish between injuries as adverse outcomes due to 
medical care or due to injuries caused by the patients’ disease or by an accident. In the clinical 
setting the term patient harm has traditionally been used when a patient suffers a harm due to 
a severe and highly unexpected event caused by the medical care given. This unresolved 
understanding of the term patient harm was not considered when the Norwegian Patient 







in 2011. They chose to use the term patient harm (pasientskade) for all events when 
implementing the GTT to measure adverse outcomes due to medical care [19]. The manual of 
the original GTT define such events as adverse events and do not use the term patient harm. 
“Patient harm” used in the Norwegian campaign included both minor events, such as catheter 
based urinary infections, and more severe events, such as injury to the ureter during a 
laparotomy. This “new” use of the term patient harm was not immediately adapted by the 
clinical health personnel in Norwegian hospitals as they have reserved this term for the severe 
events and events that could qualify for compensation through the Norwegian System of 
Patient Injury Compensation (NPE) [20]. According to the Act on Patient Injury 
Compensation [21] three criteria must be fulfilled before a claim for compensation is 
accepted. It must have been a failure in treatment (with some exceptions), economic loss of 
more than 10000 NOK and the injury could not be more than three years old when applying. 
The patient harms measured by the GTT method is mostly less severe than the events 
traditionally defined as patient harm by the clinical health personnel.  
 
The term complication does neither distinguish between events caused by the patients’ 
underlying disease, or by medical care. However, complications are often agreed as 
foreseeable unintended events due to medical care. If an event is considered foreseeable it is 
often a silent acceptance that they happen from time to time. Accepting that such events 
happen could act as an obstacle to identify, measure and prevent them. The Norwegian Patient 
Safety Program wanted to include events that were defined as complications as well as events 
that were previously not considered a patient harm (i.e.: urinary tract infection due to 
catheter), addressing all these events as patient harms.  
 
The original GTT defined the adverse outcomes due to medical care as adverse events 
(uønskede hendelser) with the definition described in table 1. As described previously, 
unplanned and unintended events have traditionally been defined as complications, if 
acknowledged at all by the clinical health personnel. The authors of the GTT focused on the 
events that harm the patients rather than errors that easily promote a perspective of whom to 
blame. Adverse events has been used in the literature for decades, but first used in relation to 








In this thesis we will investigate how the GTT’s ability to identify and measure adverse 
outcomes could be improved. We therefore decided to use the term adverse event in this 
thesis. We argue that this term includes most of the relevant events due to medical care; 











Table 2 shows the different systems that are used for reporting or measuring adverse events in 
hospitals [23]. These are unlike the methods that are used for dealing with adverse events 
such as root cause analysis, mortality & morbidity conferences, malpractice claims and 
compensation systems which all are inappropriate to use as measurement methods due to 
reporting bias. Also, selection bias, confounding bias, information bias or hindsight bias could 
influence the reporting of adverse events in the different measurement methods referred to in 
table 2. Selection bias could occur when patients are seemingly selected non-randomly, but 
for whatever reason still selected due to a specific variable such as their age, sex, department 
admitted to or selected because of the adverse event. Confounding bias can occur if an 
alternative explanation of the adverse event (which is not accounted for) is present, such as 
age. For example, if age is not adjusted for, the adverse event rates could be explained by that 
the selected patients are mainly above a certain age. If there is an error concerning the 
measurement method, it is defined as information bias. This could be present if there is 
something wrong with the measurement method. Hindsight bias could be due to that the 
outcome is known for the reviewer when determining if adverse events are present.  
 
Voluntary incident reports and patient reported outcome measures, rely on the commitment of 
health personnel and patients to report adverse events. These systems are therefore subject to 
reporting bias. The patient voice is an emerging part in the patient safety field, but there is so 
far no tradition to include patient reports in the measurement of adverse events [24]. Patients 
mostly identify problems related to doctor-patient-relationship (lack of respect, time pressure, 
rudeness, break of confidence), coordination, access (long waiting time, no appointments 
available) and communication (between doctor and patient, among health care professionals) 
[24], [25]. Medical record review is the method with highest correlation with patient reported 
events, in contrast to incident reporting by staff with no or low concordance with patient 
reported events [26]–[29]. The few studies performed suggest that patient reported outcomes 
can be included in the hospitals measurement of adverse events, but the risk of both 








Table 2 Strengths and limitations of common methods to identify adverse events  
Methods Strengths  Limitations 
Administrative data 
(e.g.: ICD 10 codes) 
Few resources required  
Inexpensive 
Utilize readily available data 
Low sensitivity- many false positives 
Requires correct diagnosis, procedures 
 
Quality indicators (QI) 
(e.g.: readmission after 30 days) 
No clinical resources needed for computerized 
systems 
Objective measure 
Inexpensive to run when first developed 
Low sensitivity- many false positives 
Requires correct documentation of the data 
 
Patient safety indicators (PSIs) 
(e.g.: decubitus ulcer) 
Do not rely on clinical judgment 
Identifies adverse events directly 
Comprehensive 
Screening tool 
Inexpensive to run when first developed 
Requires technology development 
Depend on the accuracy of the ICD-10 coding 
Some indicators are just indicators of adverse events, and not 
just an adverse event by itself 
Narrow range of adverse events 
Administrative data lack information about the severity 
Voluntary reporting 
(e.g.: incident reporting) 
Inexpensive 
Can detect latent events (near-misses) 
 
Relies on awareness and willingness of staff to volunteer 
submit event notification 






(e.g.: GTT, HPMS) 
                   
                  
                   Automatic 




No technology development required 
Works in paper records 
 
Inexpensive when first developed 
Efficient 
Objective identification of triggers 
Integrates multiple data sources 
Rely on documentation in the health record 
 
Requires extensive clinical resources 
Inter-rater reliability can vary  
Hindsight bias 
 
Technology development required  
Manual review required of the triggered records 
 
Full chart review 
 
Works in paper records 
Commonly used 
Gold standard? 
Incomplete medical records 




Patient reported outcome measure (PROM) Reflects the patients view of adverse events 
No technology development required 
Inconsistent reporting routine 
No standard definition of an adverse events 
Clinical surveillance 
(e.g.: EKG of all post-operative patients) 
Accurate and precise 
Limited to specific interventions 
Costly as all patient in a cohort are screened 
 
Observation of patient care 
(e.g.: videotaping or observation) 
Direct observation Confidentiality concerns (punishments) 
Hawthorne effect (people do not act “normal” when observed) 
Evaluates a specific situation  







1.2.3 Evaluations of measures  
 
Measures should be of high precision and with high accuracy. Precision refers to if the 
measure consistently provides the same results if it is repeated. The accuracy refers to 
whether the measure measures exactly what it is supposed to measure [30]. The precision 
describes the difference between repeated measures of the same value and the accuracy 
reflects the difference between the measured and the true value (figure 1).  
 
Figure 1 Precision and accuracy (Illustration by Laila Bjølgerud) 
 
 
The confidence interval (CI) is calculated from the observed data based on the standard error 
(SE). The confidence level is usually set to 95 %. The accuracy regarding the CI defines if the 
interval contains the true population mean while the precision refers to the width of the CI. To 
increase accuracy the confidence level is increased which will widens the CI. But if the width 







Methodological quality in studies on measurement properties can be assessed by using the 
Consensus-based Standards for the selection of health status Measurement Instruments 
(COSMIN) checklist [31]. The checklist include the measurement properties internal 
consistency, reliability, measurement error, content validity, structural validity, hypotheses 
testing, cross-cultural validity, criterion validity, responsiveness and interpretability [31]. The 
measurement properties used in this thesis is further discussed.  
 
For academic use the term reliability describes how reliable and precise the results from a 
measure are. Reliability refers to the consistency of a measure with the types: test-retest 
reliability, internal consistency and inter-rater reliability. Test-retest reliability is 
administering a test to a group of individuals, re-administering the same test to the same 
group at some later time, correlating the first set of scores with the second in a scatterplot 
computing Pearson’s r [14]. Inter-rater reliability is the correlation of scores between two or 
more reviewers who scores the same item. This is typically measured by the Cohen’s Kappa 
coefficient where kappa is the “true” agreement when accounting for agreement by chance 
[32]. This method could also be used to evaluate the agreement of repeated administration of 
a test performed by one rater (intra-rater reliability). Internal consistency is the correlation 
between different items on the same test measured by Cronbach’s alpha [33]. 
 
Validity is not defined by one definition [34]. It could be explained as the degree of which a 
concept measure what it is supposed to measure and how valid and accurate the results from 
the measure are. It could be evaluated by comparing the results of the measure to the results 
of another measure (referred to as gold standard) [35]. Content validity evaluate if the content 
of an instrument is an adequate reflection of the item to be measured. If this is obtained by 
expert opinions as a descriptive evaluation without any statistically analysis, it is called face 
validity. Construct validity evaluates if the measure measures what it is supposed to measure 
[36]. Criterion validity is how good the measure correlates with or predicts another valid and 
observable variable at the same time (concurrent validity) or later (predictive validity). For 
example, if the adverse event urinary tract infection is related to the rate of indwelling urine 
catheter used [37]. Validity is also divided in internal and external validity. Internal validity 







example, if the adverse event identified, really is caused by the intervention given in the 
actual admission. External validity is the extent to which the results can be generalized for 
other patient groups [38].  
 
A measure needs to have high reliability and high validity, but low validity is considered 
more critical than low reliability. If the measure measures some other variable and not the one 
we think it measures or if the measure is systematically wrong, a larger sample will not help, 
it will rather do more harm [36]. For example, if the method used for measuring adverse 
events have low validity, the events measured might not be true adverse events. Low 




A brief description, prevalence and source of the main types of adverse events referred to in 
the literature are presented in table 3.  
 
Table 3 Overview of the common types of adverse events 




Infections Healthcare associated infections, hospital acquired 
infections, iatrogenic infections and nosocomial infections 
such as  
• Ventilator associated pneumonia 
• Pneumonia 
• Central line associated bloodstream infections 
• Catheter associated urinary tract infections 
• Surgical site infections 
• Gastrointestinal illness 
• Blood stream infections 







Surgical  • Surgical site infections 
• Hematoma/Bleeding 
• Postoperative thromboembolism 
• Wrong site surgery 
• Retained foreign objects 









• Medical device related harms (gas/air embolism, 
burning, stent thrombosis) 
 
Obstetric/perinatal • Foetal asphyxia  
• Anal sphincter tear 
• Infections 
• Shoulder dystocia  
• Injury of intestines or urinary tract 
• Uterine rupture 
• Thromboembolism 
0.3 % Surveillance 




Falls  20 % Surveillance 
Voluntary reporting 
Chart review 
Pressure ulcer • Bedsores 
• Decubitus ulcer 
• Pressure sores 
14 % Surveillance 
PSIs 
Chart review 
Medications • Adverse drug event 
• Adverse blood infusion event 
• Adverse infusions events (vaccines) 
20 % Surveillance 
Trigger tools 
Chart review 
Diagnostics • Misdiagnosis 
• Missed diagnosis 







Infections associated with medical care has been named healthcare associated infections, 
hospital acquired infections, iatrogenic infections or nosocomial infections as opposed to 
community-acquired infections. The terms are mostly used interchangeably, but “healthcare 
associated infection”  are recommended to use when the patient recently has been 
hospitalised, had haemodialysis, received intravenous chemotherapy or resided in a long-term 
care facility in contrast to “hospital acquired” infection where the patient received the 
infection diagnose within 72 hours of admittance to hospital or developed the infection within 
10 days of discharge from the hospital [39]. The percentage of patients experiencing at least 
one healthcare associated infection is approximately 4 % in the US [40], 5.7 % in Europe and 








Adverse events following surgery  
According to the WHO almost half of the identified adverse events (48%) are related to 
surgical procedures [42]. The most frequent adverse surgical events are blood loss, surgical 
site infections and postoperative venous thromboembolism. Surgical site infections increase 
mortality, length of stay, readmissions and use of health-care services [43]. Postoperative 
venous thromboembolism is a common adverse event, occurring in 7 % of hospitalised 
patients [44] and is associated with reduced survival and substantial health-care costs [45]. 
 
Wrong site surgery could be defined as surgery on the wrong person, on the wrong body part 
or at the wrong side of the patient body [46]. Wrong site surgery and retained foreign objects 
are rare but receive major attention if they occur. Risk factors are emergency operations, 
unusual time pressures to start or complete a procedure or the involvement of different 
surgeons [47].  
 
Manufacturer-related errors, user errors and design errors of medical devices can cause 
adverse events such as gas emboli after laparoscopy/hysteroscopy, air embolism after 
infusions, stent thrombosis and burning scar after diathermic procedures [43]. In some cases it 
is difficult to identify these as the cause of the adverse event [48]. 
 
Obstetric and perinatal adverse events 
Worldwide the maternal and infant mortality rates are high mostly due to lack of access to 
medical facilities and adequate medical care [43]. The rate of obstetric related adverse events 
has been reported to less than 1 % in developed countries [49]. However, despite their 
infrequencies, obstetric events are one of the ten most common cases for claims for 
compensation in the Norwegian System of Compensation to patients ( e.g.: fetal asphyxia, 
anal sphincter tear, infections, shoulder dystocia, injury of intestines or urinary tract, uterine 
rupture and thromboembolism) [50]. 
 
Fall with injury and pressure ulcer 
Patient fall is the most common reported adverse event in the voluntary reporting systems 







events lead to harms. Negative outcome of a fall frequently includes hip fractures with 
prolonged hospitalisation. The prevalence of pressure ulcer in hospitals is estimated from 
10 % to 15 % of admitted patients and the risk factors includes immobility, friction, 
incontinence, cognitive impairment and poor nutritional status [42].  
 
Adverse drug events 
An adverse drug event can be caused both by drugs, blood products or fluid infusion. The 
adverse events related to drug treatment are one of the most common adverse events in 
developed countries. The adverse events relate mostly to prescribing, monitoring and 
administering medicines with look-alike labelling, wrong use of medication or failure to 
recognize drug interactions [43]. The consequences of an adverse drug event could be 
substantial, and it is estimated that it occurs in 1 of 16 hospitalised patients, with huge 
financial impacts [51]. Injections are one of the most common healthcare procedures with 16 
billion injections annually in developed countries including immunizations, local anaesthetics 
and contraceptives. Adverse events concerning injections are mostly related to devices that 
could transmit infections and not to the drug itself [43].   
 
Diagnostics challenges 
Diagnostics challenges include missed diagnosis, misdiagnosis and delayed diagnosis. This is 
an unexplored perspective of patient safety but is rarely registered as a type of adverse events 
on its own. This could be due to the difficulty studying the problem and the complex causes 
of it [43]. Many of the claims in the Norwegian compensation system for patient harm are 
related to delays in diagnosis or delayed or missed follow-ups. Andreasen et al found 
considerable variations of experts’ evaluations regarding the claims after alleged birth 
complications demonstrating the difficulty of studying the issues related to diagnostics 




Measuring number of patients being harmed while hospitalised was first referred by the Tort 







Study (HMPS) measured adverse events and negligence in hospitalised patients by reviewing 
patient records [22], [55]. The definition of an adverse event “as an injury that was caused by 
medical management (rather than the underlying disease) that prolonged the hospitalisation, 
produced a disability at the time of discharge, or both”, was applied. They estimated that 
adverse events occurred in 3.7 % of the hospitalised patients. The Institute of Medicine’s 
report “To Err is Human” brought the issue of measuring adverse events to national and 
international attention as they estimated that 98,000 Americans died as a results of medical 
errors every year [56]. This made measuring adverse events in hospitalised patients a growing 
focus for quality and safety in healthcare worldwide [57].  
 
Several studies followed, demonstrating that the level of adverse events was higher than first 
estimated [58]–[62]. However, comparing the results between the studies were challenging as 
the studies applied different definitions of what they had measured [63]. Although no gold 
standard to identify the true level of adverse events exists, it is a common agreement that 
adverse events is a major global health problem [1], [63]. Valid and reliable methods that 
measure adverse events are demanded. The existing systems, such as the GTT, are inadequate 
to count the actual number of events, [38] but are used for estimating the rate of adverse 
events.  
 
The WHO estimated a total of 47.7 million events when including seven different types of 
adverse events occurring annually in patients across the world [64]. In Norway, 
commissioning documents from the Ministry of Health have instructed the hospitals since 
2011 to perform the GTT to measure adverse events yearly. The most common identified 
adverse events in Norwegian hospitals during the period 2010-2015 were hospital-acquired 
infections and medication related harms [65]. Interventions to reduce adverse events were 
initiated and implemented in the hospitals as part of the Norwegian Patient Safety Program 
(“I trygge hender”). In the period from 2010 to 2017 the rate of adverse events have slowly 
decreased from 16 % to 14 % of the admissions (figure 2) [65], [66]. This rate is below the 
rate of adverse events reported in international studies [6]. The reduction of the rate in 
Norway could reflect a true reduction of rate, or it could be due to random variability. Even 







have changed [67]. Many have argued that the rate of adverse events is still persistently high, 
despite the many different interventions implemented to reduce the rate of adverse events 
[67], [68].  
 
 





As described previously, the results from the systems for dealing with and reporting adverse 
events can only estimate the number of adverse events. However, when reporting systems are 
used for estimating how many patients who are harmed, the results of this are often 
misleading. The Norwegian claims for compensation system are based on patients’ own 
claims, voluntary reports rely on health personnel to report, and severe events are investigated 
by the health supervision only if someone report the events. To illustrate how many events the 
different systems handle, we compared the reported adverse events per 100 admissions 
between the existing systems in our trust for 2013. Unfortunately, patient reported outcome 

















the NPE, the trust’s system for voluntary reporting of adverse events, the Norwegian Board of 
Health supervision and the GTT results. The GTT identified four times more adverse events 
than the other systems. We argue that this demonstrates that the GTT is the most appropriate 
system to quantify the number of adverse events. However, in most cases the events were 
reported only by one of the methods. Others have found similar results with no overlap of the 
identified events between the methods [69]. According to these findings, different methods 
might be used to reveal as many adverse events as possible. 
 
 
Figure 3 Adverse events/reported events in 2013 per 100 admissions by the different systems 





































Identification of triggers in patient records to measure adverse events was first introduced by 
Jick in 1974 [70]. Classen et al developed the method further to be used for identifying 
adverse drug events [71]. Later, these trigger tools were introduced to measure adverse events 
in surgical departments, intensive care departments and children’s departments [4], [71]–[74]. 
The trigger tools represented an alternative approach to measure adverse events [55]. The IHI 
developed the GTT initially for reviewing randomly selected paper patient records to identify 
triggers that could represent that an adverse event had occurred [5]. The GTT has successfully 
been advocated with the aim to monitor adverse events in adult inpatients demonstrated by 
widespread adoption [61], [75]–[78].  
 
The intention of the GTT was to develop an easy-to-use approach for the hospitals to identify 
and measure adverse events [5]. The results were not intended for benchmarking between 
hospitals as they have different demographic background of the patients, they treat different 
conditions, the number of inpatients differ, and the functions of the hospitals differ. These 
issues make comparing GTT results between different hospitals challenging. The developers 
of the GTT argued that the results should be used within the hospital to acknowledge the rate 
and severity of the adverse events. Once the adverse events are identified, interventions that 
can prevent them from happening should be implemented. The effect of the interventions can 
be evaluated by the use of the GTT following the rate trends over time [5] . 
 
Reviewing all inpatient records manually is impossible except in very small hospitals, hence 
the sample strategy. To obtain consistent results regarding the rate of adverse events, the 
sampling methodology needs to be truly random as the numbers of records selected must be 
identical in every sampling period from the same discharge lists. The recommended sample 
size in the GTT is ten closed inpatient records for every bi-weekly period. The patients 
eligible for selection must be 18 years or older, admitted for more than 24 hours and not be 







areas of care. The triggers in the GTT are neither developed for children and teenagers or for 
outpatients.  
 
1.3.2 Implementation  
 
The GTT is a two-step method with manual retrospective review of records: Two primary 
reviewers individually review the records for 53 specific triggers (see appendices) and 
determine if the triggers represent any adverse events, before reaching consensus (step 1). A 
secondary reviewer, a physician, authenticates their findings (step 2) [5]. The two primary 
reviewers, either nurses or other health personnel with clinical background, review the records 
independently in a predefined order; discharge codes (particularly infections, complications, 
or certain diagnoses), discharge summary, medications administration record, laboratory 
results, prescriber orders, operative record, nursing notes, physician progress note and last if 
time permits; history, consult notes and emergency department notes. The reviewers look for 
any of the triggers and possible concurrent adverse events within a maximum 20-minute 
review time limit per record. The intention of reviewing for triggers is that this provides a 
more efficient and focused review of the records to identify adverse events instead of 
reviewing the records in their entirety. This approach help select the records in the sample that 
are more likely to have documented an adverse event. The triggers are classified according to 
the care that is provided in addition a medication module: 
• General Patient care 
• Surgical care 
• Perinatal care 
• Intensive care 
• Care given in the emergency department  
 
If a trigger is identified, the reviewer checks the relevant documentation to determine if the 
trigger is related to an adverse event according to the GTT definition: “unintended physical 
injury resulting from or contributed to by medical care that requires additional monitoring, 
treatment or hospitalization, or that results in death” [5]. For example, a venous thrombosis in 







surgery is an intended outcome. The former is an adverse event and the latter is not. With this 
approach, all unintended events presented as signs, symptoms and diseases and that requires 
intervention, are considered an adverse event. To help the reviewers to determine whether an 
event is an adverse event, the following questions should be asked [5]:   
• “Would I be happy if it happened to me?” 
• “Was it a natural progression of the underlying disease?”  
• “Was it an intended result of care?”  
If the answers are no in all three questions, it is likely an adverse event. With these questions 
the method focus on how the patient perceives the event and stress that the patient’s 
perspective should be emphasized when deciding if the event is an adverse event or not. 
 
In some cases, it can be difficult to distinguish between consequences of medical care and the 
natural progression of the underlying disease as referred earlier. For example, if the patient 
suffers from a brain tumour and is treated with an operation and the patient receives blood 
transfusion after the operation- is the blood transfusion a result of an adverse event (e.g. the 
patient experienced unexpected or excessive blood loss) or was it due to the disease? In this 
case there was no reaction to the transfusion, but the transfusion was not a planned event. In 
such cases the event could be defined as an adverse event. Another example of an adverse 
event is if a patient develops a urinary tract infection while or after having an indwelling urine 
catheter. In the last case the infection is obviously due to the use of the catheter. Determining 
that this is an adverse event should be straightforward. The former described case with the 
blood transfusion is more difficult. Hence, the determination is to some extent a matter of the 
subjectivity of the reviewers although the common definition and guidelines should be used.  
 
After an adverse event is identified, the reviewer determines the severity level of the event. 
The grading of the severity is based on a modification from the National Coordinating 
Council for Medication Error Reporting and Prevention Index with categories ranging from A 
to I (NCC MERP) [79]. The categories A-D concern events that do not reach or cause any 
harm to the patient (near-misses): Category A is circumstances or events that have the 
capacity to cause adverse events, while category B is adverse events that do not reach the 







category D is adverse events that reach the patients and monitoring to confirm that no harm 
occurred is required. The few events reported through the voluntary reporting system are 
often near-misses. The category A-D is not included in the GTT definition as only events that 
cause harm to the patient are classified as adverse events in the GTT: 
• Temporary harm to the patient that required intervention (Category E) 
• Temporary harm to the patient that required initial or prolonged hospitalisation 
(Category F) 
• Permanent patient harm (Category G) 
• Intervention required to sustain life (Category H) 
• Patient death (Category I) 
 
The adverse events are often classified according to their type. Classification of types it not a 
part of the original GTT, but included in the Norwegian translation of the GTT [19] (see 
appendices).  
 
The results of the reviewed bi-weekly data are then presented in three ways: 
• Adverse events per 1,000 patient days 
• Adverse events per 100 admissions 
• Percent of admissions with an adverse event 
 
 “Adverse events per 1,000 patient days” is the recommended measure to apply when 
evaluating the rate of adverse events, since this measure accounts for the different length of 
stay in the records. Longer length of stay is associated with adverse events [80]. The “Percent 
of admissions with adverse events” is more easily understood by non-clinical staff and is 
recommended to use when the results are shared public [5]. This measure does not include 
that some patients experience more than one adverse event or the variability of length of stay 
[5].  
 
To visualize how the rate of adverse events change over time, continual data plotting in a run 
chart enables to uncover either upwards or downwards trends. The data series are plotted in a 







jumps above or over the mean/median), shifts (eight or more point above/over the central 
line), patterns (pattern that reoccur) and last looking for outliers that lie far from the central 
line. A more advanced version is the control chart in Statistical process control (SPC) which 
includes the upper and lower control limits which detect special cause variation quicker and 
more accurate [81]. Random variations are synonym with common causes that are causes that 
cannot be eliminated or determined. If sample size increases, random variation decreases. The 
SPC is used to identify special causes, or systematic errors, that might influence the process 
[82]. 
 
When identifying adverse events according to the definition given in the GTT, the 
preventability of the events is not considered. The authors of the GTT explain that this is not 
included as the definition of what is preventable constantly change. Events considered 
unpreventable today can quickly change to preventable when new innovations are introduced. 
When evaluating the adverse events over time, categorization of preventable versus 
unpreventable adverse events will be meaningless over time [5]. In Sweden, the assessment of 
preventability of adverse events has been evaluated by a grading system from 1-6; where 1-3 
are considered non-preventable and 4-6 are considered preventable [9]. Schildmeijer et al 
found great differences in the assessments of preventability and doubt the benefit of including 
this aspect as there are no standard of how to decide preventability. They argue, as other also 
have [6], that all adverse events should be considered preventable.  
 
Also, when using the GTT to identify adverse events, events due to omission is excluded as 
the definition only includes events due to medical care given. For example, if the patient does 
not receive his antithrombotic medication when indicated, and a cardiac attack occur, this 
type of adverse event is not included in the GTT. Such cases are often due to missed 
diagnoses which is difficult to reveal as discussed in 1.2.4.  
 
Hanskamp-Sebregts et al reviewed the literature concerning validity and reliability of the 
record review methods using the COSMIN checklist [83]. They evaluated the studies in 
regards to face validity and concurrent validity and they found no reference that the validity 







have been reported moderate to substantial [38]. However, the face validity of the GTT is 
evaluated to some extent by Schildmeijer et al [84]. They found that the GTT was a useful 
method to identify adverse events.  
 
Further discussions regarding challenges with identifying and measuring adverse events with 




There are some issues to consider when using the GTT as a measure of adverse events. First, 
critics argue that the GTT is too resource intensive due to time and labour required [7], [85]–
[87]. The GTT is based on a 20-minute maximum review time per record per primary 
reviewer which equates a maximum of six hours per reviewer per month if 10 records are 
reviewed bi-weekly. In addition, the time used of the authenticator is estimated to one to two 
hours per month [5]. Also, the method requires trained personnel to perform the review. The 
training is a recurring event every time a reviewer or authenticator is replaced.  
 
Second, the results of the GTT are used to make estimates of the rate of adverse events which 
are based on reviewing a small sample of records. The authors of the GTT explain that if the 
same sampling strategy is used, the method is reliable for evaluating if the rate of adverse 
events is reducing or increasing [74]. The results are less accurate when a small number of 
records is used for estimating the rate, and make it less valid as a measure of the total number 
of adverse events [88]. The number of identified adverse events are used to estimate the total 
incidence of adverse events by extrapolation. Extrapolation is a statistical method estimating a 
value (e.g.: expected rate of adverse events) based on extending a known sequence of values 
beyond the area that is certainly known [89].  
 
Third, identification of the individual triggers varies between reviewers as triggers based on 
indexed variables (i.e.; blood transfusion and dialysis) have higher agreement than triggers 
based on free text (i.e.; pressure ulcers, patient fall)  [87]. The results are to some extent 
subject to the reviewers subjectivity as inter-rater reliability between reviewers and review 








Schildmeijer et al addressed strength and limitations from the GTT reviewer’s perspective. 
They interviewed the reviewers concerning the usefulness and application of the GTT, 
preventability of the adverse events, review teams and dependence of the documentation 
provided in the health records [84]. They concluded that changing the approach of the method 
could influence the GTT results. They also meant that the reviewers should be more focused 
at looking at the patient’s perspective when deciding if an adverse event had happened.  
 
These issues are further discussed in a review of the GTT which found widespread adoption 
with different modification demonstrating its flexibility [91]. With these concerns Hibbert et 
all proposed that “the GTT should be reframed as an opportunity to identify adverse events, 
raise awareness of these within hospitals and to describe the most frequent type of adverse 
events to prioritize quality improvement”, rather than an exclusively measuring method [91]. 
This demonstrate that the GTT could be modified in order to act as a method both for 
acknowledging and measuring adverse events. 
 
Forster et al demonstrated that triggers were identified in 19-56 % of the records suggesting 
that half of the records are excessively reviewed when manual review for triggers are 
performed [92]. With automatic identification of triggers, manual reviews are only needed in 
records where triggers are identified in order to determine if the trigger is associated with any 
adverse events [87]. This reduce the number of records needed to be reviewed as the first part 
of the review (trigger identification) is done automatically. Such approach has been 
demonstrated to identify adverse drug events and adverse paediatric events with promising 
results [93], [94].  
 
Accounting for these challenges we initiated our studies to evaluate the GTT method 








2 AIMS OF THE THESIS 
 
Overall aim 
The general aim of this thesis was to evaluate the GTT method regarding sample size, 
changes of reviewers and automatic trigger identification to improve the method’s reliability 









To evaluate the inter-rater reliability when reviewers are replaced when identifying adverse 
events by the GTT.  
 
Paper III 
To evaluate a modified GTT method with automatic trigger identification to the original GTT 








3 MATERIAL AND METHODS 
3.1 Setting 
 
The GTT was implemented in Norwegian hospitals in 2011 as a part of the National Patient 
Safety Program “In safe hands” launched in 2010. All hospitals were required to review ten 
closed inpatients records randomly selected every bi-weekly period. Our trust, Nordland 
Hospital trust, chose to multiply the recommended sample size times seven. This was done 
partly because we wanted to measure adverse events separately for our seven main units, but 
we also thought that ten records reviewed bi-weekly were too small for reliable results. The 
trust implemented seven different GTT review teams corresponding to the seven different 
units. The seven review teams reviewed records discharged from their department 
respectively. The reviewers in the studies were recruited from the GTT review teams in the 
trust and had the same basic training with the GTT.  
 
The electronic health record (EHR) system was implemented in the trust in 1992 (DIPS, 
ASA). The EHRs include both free text (i.e.: discharge summaries, operative reports, 
pathology reports, radiology results, transfer of service notes, admission notes, medical 
progress notes and notes from other healthcare professionals) and indexed variables (i.e.: 
laboratory results, admissions and discharge data, diagnosis and procedure codes). In 
Norwegian hospitals medication administration, prescriber orders and vital parameters are 
still hand-written and scanned into the EHRs but are currently being digitalized and indexed. 
 
The first national Norwegian GTT results from all Norwegian hospital were used to estimate 
the number of deaths and harms caused by medical treatment. These calculations were made 
by extrapolations from the rate of the identified adverse events and contributed to major 
resistance and objections from health personnel against the GTT when published [20], [95]. 
The critics from the health personnel were mainly concerning the small sample size. Also, the 
definition of the adverse event defined as patient harm were not necessarily acknowledged by 
the clinical staff. Last, the GTT required resources which were considered unmanageable by 








3.2 Study design 
 
All records included are selected from the discharge lists in Nordland Hospital Trust (figure 4 
and figure 5). A total of 3153 different admissions were included altogether. Exclusion 
criteria were; patients aged 17 years or younger, patients admitted primarily for psychiatric or 
rehabilitation care, or patients with a length of stay less than 24 hours. The exclusion criteria 
were adapted from the GTT as the triggers are developed for adult somatic inpatients only [5].  
 
Anonymous bi-weekly discharge lists were obtained from the hospital administrative system. 
Included records were randomly selected as described in the Norwegian GTT [19]. The 
discharge lists included information regarding type of admission (acute or planned), 
diagnoses, services which the patient was admitted to, case mix index (the value is dependent 
on diagnosis and the allocation of resources to care for and/or treatment included in the 































14267 records eligable for 
inclusion in 2010
Paper I
1680 records (10 records 
from each bi-weekly period 
in seven units from January 
1th to December 31th)
Paper I
240 records (10 records 
from each bi-weekly period 
from January 1th to 
December 31th)
Paper II
120 records (10 records 
from bi-weekly periods 













In all three papers collection of data was done retrospectively. All three studies are 
observational studies. Observational studies are either prospective, retrospective or cross-
sectional studies. In prospective studies a sample of study objects are classified in some way 
and then followed over a period to see if they develop a condition. In retrospective studies the 
cases of the condition have already occurred at study initiation, and the study investigates if 
the subjects were exposed to any risk factors. In cross-sectional studies the samples are 
randomly selected at a specific point in time and cross-classified if they have the condition or 
not. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)-
checklist [96] was used to include relevant information in the papers.  
 
In Paper I, the study was designed as an observational retrospective study. We chose this 
design as the data were collected retrospectively and the rate of identified adverse events in 
two different samples were compared. In the paper we have defined it as a cross-sectional 
study. This is not correct, as patient days were accounted for. We used the appropriate 
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statistical measurements and evaluated the study as a retrospective cohort study. The 
hypothesis was: will increasing number of records reviewed affect the results of identified 
adverse events? This was examined by comparing the rate, type and severity of adverse 
events identified by the GTT in two different sample sizes; one small and one large by 
obtaining the risk ratio (RR). Altogether 1920 records selected from the bi-weekly discharge 
lists were included. The large sample included records selected as 10 records bi-weekly from 
the seven units discharge lists (n=1680) while the small sample included ten records selected 
bi-weekly from the trust´s discharge lists (n=240) (figure 4). The manual review to identify 
triggers and adverse events differed in some way between the two samples. The records in the 
large sample were reviewed by one of three primary reviewers (two physicians and one nurse) 
and all three reached consensuses regarding the adverse events they all had identified 
separately. The records in the small sample were reviewed as described in the GTT; two 
primary reviewers (nurses) individually reviewed the records and reached consensus 
regarding the adverse events before a secondary reviewer (a physician) authenticated their 
common findings [5]. The reviewers of both samples were the same, except that one of the 
physicians from the small sample was replaced by a nurse in the large sample.  
 
Paper II was designed as an observational cross-sectional study including 120 records (figure 
4). We did not consider an alternative design as the study compares agreement between 
different reviewers regarding the prevalence of identified adverse events within a sample. The 
study evaluated the reproducibility of the method. The length of patient stay in the different 
records do not affect the results as the review teams review the same 120 records. Three 
review teams review the records as described in the GTT with two primary reviewers and one 
secondary reviewer [5]; Team I (three consistent reviewers- two primary reviewers and one 
secondary reviewer), Team II (one of the two primary reviewers or/and the secondary 
reviewer from Team I are replaced for different review periods) and Team III (no identical 
reviewers with Team I or Team II). The presence, type and severity of the adverse events 
identified by the three review teams were compared to assess the inter-rater reliability 








Paper III describes an observational cross-sectional study including 1233 records. The study 
evaluates two different methods to identify and measure adverse events, the modified GTT 
method versus the original GTT method. As in Paper II we did not consider an alternative 
design. 70 records were selected bi-weekly from the discharge lists from March 1th to 
December 31th 2013 (figure 5), but 167 records were excluded as data for these records were 
missing in the automatic trigger system. A modified GTT method, including automatic 
identification of triggers with manual review of the triggered records performed by a 
physician, was compared to the original GTT method [5]. The original GTT method included 
manual review of triggers and possible corresponding adverse events by two primary 
reviewers and authentication of their findings regarding adverse events was performed by a 
secondary reviewer. The identified adverse events by the modified GTT method were 
compared to the adverse events identified by the original GTT method. The concurrent 





In all three papers we evaluated the use of the GTT. The definition of an adverse event 
adopted from the GTT was applied in all three papers [5]. The training of the reviewers 
included the following understanding of how to determine if an adverse event was present: If 
the patient had experienced an unplanned event that led to either treatment, prolonged stay, 
permanent injury, immediate treatment to sustain life or death, the event was defined as an 
adverse event. The perspective of the patient was assessed by asking the questions as 
addressed in the GTT, mentioned in the chapter 1.3.2. [5]. Near misses that did not lead to the 
above criteria were not counted as adverse events and preventability of the adverse events was 
not evaluated.  
 
The reviewers followed the approach as described in 1.3.2 except from the review team who 
reviewed the records of the large sample in Paper I. The triggers identified by the review 
teams and by the automatic trigger identification system was recorded in the databases. If the 







the databases. The categories of type of adverse events was adopted from the Norwegian GTT 
manual and sub classified in these main categories [19]: 
• Surgical complications  
• Bleeding/thrombosis  
• Medication harm  
• Patient fall  
• Pressure ulcers  
• Obstetric harm  
• Other 
 
3.4 Methodological consideration 
 
Possible bias, presented in 1.2.2, could be present in all three studies. In Paper I selection and 
confounding bias are most likely to occur as the selection of records differed between the two 
samples. In Paper II hindsight bias could occur as the reviewers reviewed the records with 
different reviewers. The subjectivity of the reviewers could influence the results as the 
reviewers decided to some extent by themselves if the event was an adverse event or not. 
Selection bias is less likely in Paper II and Paper III as the reviewers reviewed the same 
records. In all three papers information bias could be present, as the findings of the adverse 
events rely on documentation in the records. Also, identification of triggers relies on that the 
information needed to identify a trigger is documented in the patient records. We consider 
that the results could be generalized for patient populations elsewhere.    
 
3.5 Statistical analyses 
 
The size of the small sample size in Paper I and Paper II are equal to the recommended 
sample size in the GTT with ten records selected bi-weekly. The size of the large sample in 
Paper I and Paper III with 70 records selected bi-weekly is the same as the total sample size 
used in our trust for the GTT. Power estimates of the sample sizes in Paper I was done with 
80 % power. We assumed that the incidence of adverse events was 20 %. We then needed at 







significant results. In Paper II and Paper III kappa statistic was used. Power estimates was not 
performed, but if the CI is narrow then the power is considered good. The primary endpoint in 
all three papers was the rate of identified adverse events. Secondary endpoints were severity 
and types of adverse events.  
 
To examine the means of the adverse event rates in the different samples, SPC charts were 
applied using QI Macros for Excel. The SPC charts include control limits, which are 
calculated based on the values presented and are ± 3 standard deviations from the central line 
(average). Any variation between the control limits are common causes of variation, while 
variation above or under the control limits are due to special cause variation. 
  
Poisson regressions in Generalized linear models were applied to compare the rates of adverse 
events, severity level and categories of types of adverse events between the different sample 
sizes. Poisson regression was selected as it accounts for variation of number of cases and 
length of stay. Adjustments of demographical variables were done by including these as 
covariates. RR was obtained.  
 
We used Cohen’s kappa to determine the inter-rater reliability. For nominal data (value of 0 if 
no agreement and value of 1 if perfect agreement) kappa statistic was applied. For ordinal 
data (values from 1 to usual not more than 4 or 5 is applied for the different categories) 
weighted kappa was applied. Weighed kappa was applied when comparing severity level as 
we decided that it was less agreement if the event was rated category E by one reviewer and 
category H by another reviewer than rated category E versus category F. If no adverse events 
were identified the value of 1 was applied, if the adverse event was severity category E value 
2 was applied, severity category F value 3 was applied, severity category G value 4 was 
applied, severity category H value 5 was applied and severity category I value 6 was applied. 
The interpretations from Landis and Koch was used for the Cohen kappa coefficient: poor 
(<0.0), slight (0.00-0.20), fair (0.21-0.40), moderate (0.41-0.60, substantial (0.61-0.80) and 
almost perfect (0.81-1.00) [97]. The inter-rater reliability has been used to evaluate measures 








Statistical association of categorical variables was assessed by Chi-square test while 
continuous data were compared using independent t-tests. To compare the number of adverse 
events identified by different methods or by different teams, Paired t-tests were used. When 
evaluating the performance of the modified GTT method, the original GTT method was set as 
gold standard. We calculated sensitivity (recall as used in Paper I), positive predictive value 
(or precision) (PPV) and specificity with their respective 95 % confidence intervals (CI) to 
evaluate the validity of the modified GTT method [99]: 
 
𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 =
𝑁𝑜. 𝑜𝑓 𝑐𝑜𝑟𝑟𝑒𝑐𝑡 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑟𝑒𝑐𝑜𝑟𝑑𝑠 𝑖𝑑𝑒𝑛𝑡𝑖𝑓𝑖𝑒𝑑 𝑏𝑦 𝑡ℎ𝑒 𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑 𝐺𝑇𝑇 𝑚𝑒𝑡ℎ𝑜𝑑




𝑁𝑜. 𝑜𝑓 𝑐𝑜𝑟𝑟𝑒𝑐𝑡 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑟𝑒𝑐𝑜𝑟𝑑𝑠 𝑖𝑑𝑒𝑛𝑡𝑖𝑓𝑖𝑒𝑑 𝑏𝑦 𝑡ℎ𝑒 𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑 𝐺𝑇𝑇 𝑚𝑒𝑡ℎ𝑜𝑑




𝑁𝑜. 𝑜𝑓 𝑐𝑜𝑟𝑟𝑒𝑐𝑡 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑟𝑒𝑐𝑜𝑟𝑑𝑠 𝑖𝑑𝑒𝑛𝑡𝑖𝑓𝑖𝑒𝑑 𝑏𝑦 𝑡ℎ𝑒 𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑 𝐺𝑇𝑇 𝑚𝑒𝑡ℎ𝑜𝑑
𝑁𝑜. 𝑜𝑓 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑟𝑒𝑐𝑜𝑟𝑑𝑠 𝑖𝑑𝑒𝑛𝑡𝑖𝑓𝑖𝑒𝑑 𝑏𝑦 𝑔𝑜𝑙𝑑 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑
 
 
The CI for sensitivity, PPV and specificity was calculated using the Wilson score method 
[100]. CI for Cohen’s Kappa was calculated as κ± 1.96*SE. 
 
For all analyses, we used two-sided tests. The significance level was set at 5 % and 95 % CI 
were reported if relevant. The statistical analyses were performed using the SPSS statistical 
package, version 22.0 (SPSS Chicago, IL, USA).  
 
When performing a statistical test there is always a chance of committing Type I error 
(incorrectly rejecting a true null hypothesis). The maximum probability of Type I error equals 
the specified significance level (5%) and we reject the null hypothesis whenever the p-value is 
lower than 0.05. In situations where we have multiple tests the Type I error probability in at 
least one test would be higher than 5 %. One way of reducing this error probability is to 
reduce the significance level proportionally to the number of tests (Bonferroni adjustments). 
Regardless of significance level, adjustment for other variables (age, length of stay etc.) 








3.6 Ethical consideration 
 
The studies were performed in accordance to the Helsinki Declaration of 1975, and approved 
by the Norwegian Regional Committee for Medical and Health Research Ethics (Protocol ID: 
2012/1691) and the Data Protection Office at the Nordland Hospital trust.   
 
The information from the patient records were anonymised when extracted from the hospital 
administrative system and included in databases. The databases were hosted within an 
encrypted environment restricting the access to granted personnel only.   
 
Information from medical records can be obtained for the purpose of internal control and 
quality assurance according to the Norwegian Health Professional Act. The trusts are required 
to obtain information and develop statistics about unintended events involving patients 
according to the regulations of the Norwegian Health Specialized Service Act. The health 
information can be obtained without consent in such cases. According to the same act the 
health services are also obligated to report severe adverse events to the Norwegian Board of 
Health Supervision. 
 
The need for patient consent was waived for the records included in Paper III and for the 
largest sample in Paper I on the basis of :1) the records had already been selected and 
reviewed as a part of the trust’s measurement of adverse events; 2) retrospectively collecting 
informed consent from patients or relatives of deceased patients would be costly with respect 
to time and money and might be considered a burden or inconvenience for the 
patients/relatives; 3) that the risk of being included and disadvantages of not being informed 
are considered minimal. This is in accordance to the criteria for waiving consent by Baker et 
al [101]. In Paper I we included a sample of records (n=240) that were not already selected 
for the trust’s measurements of adverse events. 120 of the 240 records used in Paper I were 
also used in Paper II. We argued that these patients should be contacted and asked for consent 
when we applied for approval of the study. 26 denied consent or did not respond to the 
consent letter. To include the correct amount of records (ten records bi-weekly), replacements 







patients had denied consent or not responded. The “new” included patients were also asked 
for consent. We included information in the consent letter that the patients could contact the 
study leader upon questions and that they at any time could withdraw their consent. 
Retrospectively we considered that asking these patients for consent was not necessary in 
concordance with the referred criteria.  
 
There is great variability in the interpretation of research issues related to patient safety and 
quality. Research committees and national legislations practice consent waiving differently 
[102]. The WHO recommend that when in doubt, all projects should be submitted to the ethic 
committees before study start, to determine if consent is needed [103]. The ethic committees 
can waive the usual requirement of individual informed consent when the research involves 
minimal risks and obtaining consent would be impracticable [104]. An alternative when 
formal consent is waived, is to provide information of the studies being performed either by 
posters, leaflets or as a part of the general patient information [103]. In our trust we provide 
information in the lobby regarding that patient records are being reviewed to identify adverse 
events, along with the identified rate of adverse events (figure 6). 
 













The thesis examined different methodological aspects of the GTT record review method. In 
the first part of the study, the results suggested that increasing the sample sizes narrowed the 
CI thereby giving more precise results that can be extrapolated to institutional levels. The rate 
of identified adverse events was higher in a large sample compared to a small sample. The 
second part of the study evaluated how a larger sample of records could be efficient reviewed 
with valid results. The review of the triggered records should be done with consistent 
reviewers and automatic trigger identification enabling increasing the sample size without 
increasing the resources needed.  
 
4.1 Patient characteristics 
 
Demographic variables for the included 3153 patients compared to all records eligible for 
selection in 2010 and 2013, are presented in table 4. Median age was 64 (range 18-84) years. 
Most of the patients were women (60 %). Adverse events were identified in 655 (21 %) of the 

































     N (%)     N (%)   
     Bodø 
     Lofoten 
     Vesterålen  
2301 (73) 
  395 (13) 
  457 (15) 
            17153 (66 ) 
              4201(16) 




     
   ≤ 65 





            12335 (48)           62.1 (20.7) 
            13603 (52)                                  
  
 
Type of admission 
     
   Acute 
   Planned 
  2240 (71) 
    913 (29) 
           19092 (74) 




     
   Male 
   Female 
1258 (40) 
1895 (60) 
            11189 (43) 
           14749 (57) 
  
 
Number of patient days 
     
   3≤ 





          11082 (43)               6.1 (6.5) 
          14856 (57)  
  
 
Adverse event present* 
     
   Yes  
    No 
  655 (21) 
2498 (79) 
    
 







4.2 Paper I 
 
We found that a large sample size of 70 records selected bi-weekly identified 45 % (RR: 1.45 
CI: 1.07-1.97) more adverse events per 1000 patient days, than a smaller sample size of ten 
records selected bi-weekly. In the large sample 39.3 adverse events per 1000 patient days (CI: 
35.8-43.1, SE: 1.86) were identified while in the small sample 27.2 adverse events per 1000 
patient days (CI: 20.3-36.4, SE: 4.05) were identified. The difference was significant (p=0.02, 
CI: 1.04-1.93). As expected, the CI was narrower and the SE was lower in the large sample 
than in the small sample. However, there was no difference regarding variation over time 
between the samples. This is in accordance with the main purpose of the GTT; to monitor the 
rate of adverse events over time. There was no significant difference between the samples 
regarding length of stay, average age or sex. When adjusting for services, diagnosis, case mix 
index, surgical treatment, acute or planned admission and numbers of transfers related to the 
index hospitalisation, the overall results were not altered. 
 
SPC charts were applied to compare the mean rate of adverse events over time to examine if 
any of the tests of special causes were positive. In the small sample test 1 was positive (i.e.; 




          
          
          
          
          
          
          
          
          
          
          
          
          
          




























































































































Hospital acquired infection was the most frequent type of adverse event in both samples 
followed by surgical related harms, medication harms, bleeding/thromboembolism, patient 
falls, pressure ulcer and obstetric harms (figure 8). No significant difference between the 
samples regarding the types of adverse events or the severity level was identified. 57 % of the 
adverse events identified in the large sample were defined as category E (harms requiring 
interventions) compared to 56 % in the small sample (RR: 1.5 p= 0.054, CI; 0.99-2.26). 
Respectively 39 % and 33 % of the adverse events were category F (RR: 1.69 p=0.051, CI: 
1.00-2.86) and 3 % and 11 % were defined as severe adverse events (category G, H or I) (RR: 
0.47 p=0.14, CI: 0.17-1.27).  
 
Figure 8 Types of adverse events identified 
  



















4.3 Paper II 
 
120 records were reviewed by three review teams; Team I, Team II and Team III. Team I and 
Team II had one or two identical reviewers throughout the review of the 120 records. Team 
III had none identical reviewers with Team I and Team II. Team I identified 23 adverse 
events, Team II identified 20 adverse events and Team III identified 18 adverse events (figure 
9). Team I and Team II identified six identical adverse events. The same six adverse events 
were not identified by Team III. In seven records Team III disagreed with Team I in regard of 
type of adverse event, while Team II disagreed to Team I in three records.  
 













We found that the agreement in regards of presence of adverse events was substantial 
(κ=0.64) when one or two of the reviewers were identical (Team I versus Team II) compared 
to moderate (κ=0.47) when none reviewers were identical (Team I versus Team III). 








Team II Team III 
   
 
   









was substantial between Team I and Team II compared to between Team I and Team III 
(table 5).  
 
Table 5 The level of agreement between Team I and Team II and between Team I and Team 
III in terms of adverse events and severity level 
 Team I vs Team II (kappa 
coefficient, 95 % CI) 
Team I vs Team III 
(kappa coefficient, 95 % CI) 
Presence of adverse events* 0.640 (0.434-0.846) 0.468 (0.232-0.703) 
Number of adverse events** 0.661 (0.479-0.842) 0.468 (0.278-0.694) 
Severity level** 0.652 (0.469-0.836) 0.442 (0.260-0.624) 








4.4 Paper III 
 
We evaluated the performance of a modified GTT method (figure 10). The modified GTT 
method included manual reviews for adverse events in 658 records identified with triggers by 
an automatic trigger identification system. The automatic trigger system screened 1233 
records. The results were compared to the original GTT method which included manual 
review of all 1233 records to identify both triggers and adverse events. 
 




The modified GTT method identified the same rate of adverse events as the original GTT 
method; 35 adverse events per 1000 patient days. Sensitivity, PPV, specificity and reliability 
for records identified with adverse events were respectively 0.59, 0.58, 0.92 and 0.51 for the 
modified GTT method in respect to the original GTT method as gold standard. The total 
manual review time in the modified GTT method was 23 hours, while the manual review time 
using the original GTT method was 411 hours. 
 
Number of records identified with adverse events (15.3 % versus 15.1 % of the total number 
of records, p=0.81, CI; -0.02-0.02) and number of identified adverse events (p=0.90, CI; -







GTT method. The modified GTT method reduced the number of records needed to be manual 
reviewed by 50 % (figure 11).  
 
Figure 11 Number of records identified with triggers and adverse events by the modified 
GTT method and the original GTT method 
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5.1 Summary of strength and weaknesses 
A summary of the strengths and weaknesses of the studies included in this thesis are 
presented in Table 6. 
 
Table 6 A summary of strength and weaknesses 
Weaknesses Strengths 
Study design 
Only two sample size (10 vs 70 records bi-weekly) 
compared 
Large number of records reviewed from bi-weekly periods 
Different sampling methods Adjusted for different sample methods 
 Records were randomly selected 
No power estimates were performed The sample size recommended in the GTT was applied 
Some of the triggers were not possible to identify 
automatically  
Automatic identification of 42 triggers 
Small samples increase the risk of type 2 error  
Information bias due to retrospective collection of data  
No validation to an external patient cohort The results correspond with other studies 
Cross-sectional studies require large samples Observational study design allows for different variables 
Reviews 
 All reviews were performed by expert reviewers 
 Reviewers underwent the same training program 
Data rely on documentation in the EHR  
Identification of adverse events rely on triggers identified A common definition of adverse events was applied in all paper 




 Generalized method was used accounting for different length of 
stay and different sample sizes 
 Performance of a modified GTT method demonstrated a valid 
method to measure adverse events 
Manual review is difficult to reproduce and compare 
between studies 
Inter-rater reliability between reviewers was obtained when 
applicable and was substantial 
A minimum P-value has increased type 1 error (false 
positive) and difficult to compare across studies 
A minimum P-value approach is appropriate for exploratory 








5.2 Paper I 
 
Our study demonstrated that increasing the sample size affected the rate of adverse events, 
while the type and severity of identified adverse events were not influenced. 1.45 more 
adverse events per 1000 patient days were identified in the large sample (n=1680 records) 
than in the small sample (n=240). We argue that the rate of adverse events identified in the 
large sample is more representative and precise than the rate of adverse events identified in 
the small sample due to the narrow CI in the large sample.  
 
A narrow CI makes the results more precise, and extrapolation with such results makes 
estimates of the total number of adverse events less uncertain. Many have debated the 
difficulty with estimating rates of adverse events based on small samples, and our results 
demonstrate this challenge [63], [105], [106]. Also the infrequent severe adverse events are 
often missed when sampling approaches are used [107]. No severe adverse events (category I) 
were identified in the small sample. Due to the infrequently occurrence of severe adverse 
events, other methods should be used to monitor these specific types of events, for example, 
investigating all hospital deaths [108], [109]. 
 
In the small sample there were an outliner with excessive patient days. We tested if exclusion 
of 10 % of the patient days form each sample altered the results. In the large sample 24 
records with a total length of stay of 1150 patient days were excluded. In the small sample 
two records were excluded with a length of stay of 197 patient days. The result was not 
altered as the RR was 1.55 (CI: 1.1-2.1). In the large sample the rate was 39.2 adverse events 
per 1000 patient days while in the small sample the rate was 25.3 adverse events per 1000 
patient days. As an explanation of the difference in rate, we therefore argue that this is most 
likely due to random variation as other explanations were adjusted for.  
 
Several studies refer to high sensitivity [6] and acceptable reliability [7], [110] of the GTT, 
but the impact of the sample size has been discussed only by few. To our knowledge this study 
is the first attempt to assess the impact of the sample size on the results identified with the 







population in our trust. Kennerly et al, among others, proposed that the sample size of records 
to be reviewed should be adjusted to the hospital size [6], [75], [111].  
 
It is important to consider the Simpsons paradox when evaluating the results. This is implying 
that statistical results from aggregated data could give a different result when extracting the 
results to a group-level analysis [112]. This is important to be aware of when using the 
statistics for causal interpretations. We therefore adjusted for the variations such as case mix, 
if surgery was performed, case mix index, hospital locations, units and type of admissions, 
which were correlated to the index discharges (the sources of the selection of the records). 
When adjusting for these variations the results were not changed; the rate of adverse events 
was still significantly different between the two samples while the type and severity were not. 
The results did also not differ when adjusting for demographic variables such as gender, age 
and total length of stay. We do therefore not consider that the Simpsons paradox is a relevant 
problem in this study. 
 
Another factor is that we do not have any information of the patient records in the small 
sample where patients had denied consent or refused to answer. These patients could have 
experienced an adverse event and would not participate because of a bad experience with the 
trust. This could bias the result from the small sample as the aim was to compare the rate of 
adverse events between the samples.  
 
The SE of the mean represents the degree of the variability of the mean. The SE is low in the 
large sample while the small sample has a higher SE. The means of the rate of adverse events 
identified in the large sample has less random variability. With these assumptions we consider 
that a larger sample include more trustworthy results. The smaller sample is less resilient for 
outliners as there are too few records included.  
 
The review process of the two samples differed slightly as described in the study design. To 
adjust for this possible bias, we assessed the agreement between the different authentication 







authentication processes did not impact the results [113]. We argue that the difference in 
review process between the samples did not influence the results in our study. 
 
The power estimate of the large sample size was based on a difference of 7 % between the 
samples with 80 % power. The difference in the identified adverse events rate between the 
samples was 45 %. We therefore assume that the sample size was large enough. A larger 
sample size could reflect the population more accurate than a smaller sample and the rate of 
adverse events that were identified in a larger sample could be more reliable [114]. Further, 
we could have included more records by enhancing the study length period. Variation of 
number of patients and medical care given differ more between the different parts of the year 
than between two different years. We assumed that inclusion of records from one year was 
enough to obtain reliable results. 
 
Other limitations when interpreting the results, is the categorization of types of adverse events 
which are not mutually exclusive. The determination of type of adverse event is based on the 
subjectivity of the reviewers as no common definitions of which type of adverse events to 
include in the different categories exists.  
 
The length of stay in the records, which is the denominator in the estimated rate of adverse 
events per 1000 patient days, must be accounted for when comparing the means of the rate of 
adverse events. We therefore applied the Poisson regression in the generalized linear models 
as it is appropriate for rate data when the dependent variable is a count of events divided by 
some measure of that unit’s exposure, i.e. number of adverse events per 1,000 patient days. 
The difference in number of records included in the two samples is also being accounted for 
when using this statistical test. The RR could then by obtained. The wide control limits in the 
SPC chart of the mean rates in the small sample demonstrated that these rates did vary more 
than the rates identified in the large sample.  
 
Our results imply that the recommend sample size of ten records reviewed bi-weekly is too 
uncertain. Hence, further studies are needed to determine whether there is an optimal sample 







larger sample sizes requires more resources. Until further studies, we have suggested using a 
relative increase in sample size to 8–10% of total number of discharges when using the GTT 
to achieve a narrow CI and hence more precise results. The increase in sample size requires a 









5.3 Paper II 
 
In this study we evaluated the inter-rater reliability as we compared the results from different 
review teams who reviewed the same records. Others have examined the inter-rater reliability 
and have found at best a moderate to substantial agreement [98]. However, in this study we 
demonstrated substantial inter-rater reliability between review teams where at least one of the 
reviewers were identical. Moderate inter-rater reliability was found between review teams 
with no identical reviewers.  
 
Members in the review teams performing the GTT are often replaced due to practical issues 
such as relocation of work place, sick leave and maternity/paternity leave. To our knowledge, 
this is the first attempt to assess inter-rater reliability between review teams experiencing 
replacement of reviewers to varying degrees. Evaluating the inter-rater reliability between all 
different teams, as replacement of all reviewers, have been described previously and reported 
to be poor [68]. We therefore evaluated how the results are affected when review members 
are changed except from one of the primary reviewers. We chose to keep one of the primary 
reviewers consistent as the GTT recommend that the primary reviewers are the ones who 
conduct the first screening of the records and therefore most important to keep consistent [5]. 
We considered replacement of both primary reviewers as equal to replacement of all review 
members as the primary reviewers perform the initial review. The secondary reviewer only 
authenticates the findings without accessing the records routinely. Unlike our assumptions 
O’Leary et al highlighted that the variation was higher between confirmation of adverse 
events than for identification of potentials adverse events [115]. 
 
The variables concerning the reviewers such as review experience, clinical background and 
years of experience could influence the results. The mean years of clinical experience was 
18.3 years (range 7-29) of the reviewers and the total mean years of review experience of the 
three teams were 2 years. To evaluate the agreement of identified adverse events between the 
teams, the kappa statistics was used. This analysis is not able to adjust for clinical experience 
between the teams. We have therefore not discussed any influence such as psychology or 







dynamics which was not the intention of this study. We intended to evaluate a practical 
solution with a pool of reviewers performing the GTT at different times without influencing 
the results.  
 
Our findings indicate that hospitals can rely on rotating reviewers from a consistent pool of 
reviewers in order to optimize resources. With this approach hospitals are encouraged to 
perform the GTT even if they experience frequent replacement of reviewers. However, the CI 
is wide which indicate that the sample size might not be large enough. Our results must 









5.4 Paper III 
 
Identifying and measuring adverse events in hospitalised patients is challenging. So far, we 
consider the GTT the most robust method to measure adverse events in comparison to most 
other existing methods. The practical disadvantage with the method being resource intensive, 
can to a certain extent be addressed by automating the trigger identification. We developed an 
automatic trigger identification system to automate 42 of the GTT triggers. The study 
demonstrated that the modified GTT method using automatic trigger identification is a valid 
measure in respect to the original GTT method. To our best knowledge such study has not 
been performed previously. 
 
Since the late 90’s Classen et al along with others, have demonstrated computerized 
surveillance of adverse drug event by automated detection of triggers that could represent 
possible adverse events [116]–[121]. When triggers are automatically identified, only the 
records with triggers are reviewed manually to determine if the trigger represents an adverse 
event. This approach has showed promising results [93], [94].  
 
The “gold standard” of determination of an adverse event has traditionally been the judgment 
of clinicians [122]. Automatic identification of adverse events based on administrative data 
have showed disappointing results [123]. With such approach the positive predictive value are 
reported to be low, ranging from 12-30 % [124]–[136]. We consider that a manual review is 
still needed to determine if the triggers automatically identified, represent an adverse event 
according to the GTT definition applied in the study. However, machine learning is slowly 
integrated in medical decisions, such as radiology imagination and treatment outcomes [137], 
[138]. In the future it is therefore possible that adverse events can be identified automatically. 
We consider that the automatic trigger identification system could be further developed to a 
system that can predict which patients who are at risk to experience an adverse event enabling 
the clinicians to act in real-time to prevent adverse event. 
 
The modified GTT method, with manual review of only records with automatic identified 







number of manually reviewed records were reduced by 50 % with the modified GTT method 
(n=658) compared to the records manually reviewed in the original GTT method (n=1233). 
This is because the original GTT method demands the reviewers to screen all records to 
identify any triggers and then do a more in-depth review when triggers are identified to find 
any possible corresponding adverse events. In the modified GTT method the automatic trigger 
identification system performed the screening of triggers and manual review was only 
performed in the triggered records. The time used with the modified GTT method was only 
6 % of the time used with the original GTT method. We consider this an exceptional result. 
Others have showed that the time using computerized strategies is 20 % compared with the 
time used with manual strategies [107], [139]. 
 
We found good agreement between the two methods with regards to the records identified 
with adverse events (κ=0.51 CI: 0.44–0.57). Our results demonstrated better agreement 
between the automated method versus all manual methods, compared to other studies, who 
have found only up to 12 % agreement [115], [139]. The modified GTT method identified 
59 % of the records identified with adverse events by the original GTT method (110 of 186 
records). The variation between the methods concerning the difference of number of records 
identified with adverse events could be explained by using different review team. The 
automatic triggered records were reviewed by one physician. The original GTT method was 
performed as described in the GTT manual [5]. We have argued that using different reviewers 
may affect the results as demonstrated by for example O’Leary et al [115]. However, we 
concluded that this did not bias the results in this study. 
 
A recent review by Hibbert et al found that the GTT identified adverse events in 7-40 % with 
a cluster around 20-29 % of the reviewed records [91]. O’Leary et al found that 22- 26 % of 
records identified by automatic system were confirmed with adverse event [115]. The 
modified GTT method confirmed adverse events in 33 % of the triggered records. To examine 
how many of the total number of records are triggered, we ran the automatic trigger 
identification system for all admissions eligible for inclusion in the GTT in 2017. The 
automatic trigger identification system identified at least one trigger in 62 % (n=10807 







30 % of the triggered records in the study, constituting 15 % of the original record sample. If 
we apply this result to the aggregated numbers of 2017, the estimated number of records with 
adverse events would be 3242 records; or one of five hospitalised patients are harmed due to 
medical care. This emphasize the modified GTT method as a valid method to measure 
adverse events  [6]. 
 
We have not considered the financial aspect of the automatic tool as this was beyond the 
scope of the study. The GTT method is criticized because it is resource intensive due to time 
and personnel required. We have therefore evaluated how to reduce resources in regard to 
personnel and time needed for reviewing the records. 
 
Our results recommend that the modified GTT should be preferred rather than the original 
GTT method, as the modified GTT method is less resource intensive. The resources saved by 
using the modified GTT method is considerable, enabling increasing the sample size as 










6. CONCLUSION  
 
In Paper I we found that increasing the sample size provides a narrower CI, reduce the 
random variation and increase the precision of the results. The rate of identified adverse 
events was higher in a large sample than in a small sample. We argue that a large sample 
should be preferred as this is a more reliable source for extrapolation of rates when 
calculating the total number of adverse events. In Paper II we demonstrated that keeping one 
reviewer consistent provide more reliable results. Using the modified GTT method, as 
demonstrated in Paper III to identify and measure adverse events, is a time-effective strategy. 
We suggest that our findings can guide hospitals to identify and measure adverse events more 









7. IMPLICATION FOR FUTURE RESEARCH 
 
The results of these studies lead to suggestions of some changes in the practical use of the 
GTT. First, we suggest that the sample size should be increased, second, we argue the 
importance of keeping one of the primary reviewers consistent and finally we introduced 
automatic trigger identification as a successful alternative approach to the manual GTT. These 
implications could facilitate more widespread adoption of the GTT as a method to identify 
and measure adverse events.   
 
Future research could include a comparison of review of the automated triggered records by 
two different review teams or by two different reviewers. This could be done as a cross-
sectional study comparing the rate of identified adverse events but also comparing the 
findings in each record by the two review teams/reviewers. If the agreement is substantial it 
could demonstrate that automatic trigger identification increase the agreement with an 
objective screening of the records.  
 
Also, an automatic trigger identification system could be developed further to a prospective 
approach. Sammer et al presented a system allowing for real-time bedside intervention, real-
time trend analysis and continued learning about harm measurement using a sociotechnical 
approach of people, process and technology [107]. Their framework emphasizes the 
framework of Donabedian [140] to assess quality of care; structure, process and outcome. We 
believe that moving to a prospective system, to identify patient at risk, would be beneficial for 
the clinical health personnel as it allows them to prevent adverse events from happening to the 
actual patient. Novel technologies such as identifying risk factor for developing adverse 
events must be integrated in the EHR. This could be performed either as a cohort study or as a 
cross- sectional study depending on the study questions. Such prospective system could be 
used to improve clinical outcome, optimize treatment, reduce the financial burden of patient 
harm, reduce the burden for involved health personnel and most importantly; reduce the 










[1] M. A. Makary and M. Daniel, “Medical error—the third leading cause of death in the 
US,” BMJ, vol. 353, 2016. 
[2] L. Adler et al., “Impact of Inpatient Harms on Hospital Finances and Patient Clinical 
Outcomes.,” J. Patient Saf., vol. 14, no. 2, pp. 67–73, Jun. 2018. 
[3] W. Martinez, L. S. Lehmann, Y.-Y. Hu, S. P. Desai, and J. Shapiro, “Processes for 
Identifying and Reviewing Adverse Events and Near Misses at an Academic Medical 
Center.,” Jt. Comm. J. Qual. patient Saf., vol. 43, no. 1, pp. 5–15, Jan. 2017. 
[4] R. K. Resar, J. D. Rozich, and D. Classen, “Methodology and rationale for the 
measurement of harm with trigger tools.,” Qual. Saf. Health Care, vol. 12 Suppl 2, pp. 
ii39-i45, 2003. 
[5] F. Griffin and R. Resar, “IHI Global Trigger Tool for measuring adverse events 
(Second Edition),” IHI Innov. Ser. white Pap. Cambridge, Massachusetts Inst. Healthc. 
Imrovement;, pp. 1–44, 2009. 
[6] D. C. Classen et al., “‘Global trigger tool’ shows that adverse events in hospitals may 
be ten times greater than previously measured.,” Health Aff. (Millwood)., vol. 30, no. 4, 
pp. 581–9, Apr. 2011. 
[7] J. M. Naessens et al., “A comparison of hospital adverse events identified by three 
widely used detection methods.,” Int. J. Qual. Health Care, vol. 21, no. 4, pp. 301–7, 
Aug. 2009. 
[8] T. O. Mattsson, J. L. Knudsen, J. Lauritsen, K. Brixen, and J. Herrstedt, “Assessment 
of the global trigger tool to measure, monitor and evaluate patient safety in cancer 
patients: reliability concerns are raised.,” BMJ Qual. Saf., vol. 22, no. 7, pp. 571–9, Jul. 
2013. 
[9] K. Schildmeijer, L. Nilsson, K. Arestedt, and J. Perk, “Assessment of adverse events in 
medical care: lack of consistency between experienced teams using the global trigger 
tool,” BMJ Quality & Safety, vol. 21. pp. 307–314, 2012. 







Lewalle, “Towards an International Classification for Patient Safety: key concepts and 
terms,” Int. J. Qual. Heal. Care, vol. 21, no. 1, pp. 18–26, Feb. 2009. 
[11] W. Runciman, “Shared meanings: preferred terms and definitions for safety and quality 
concepts,” Med. J. Aust., 2006. 
[12] G. Parry, A. Cline, and D. Goldmann, “Deciphering harm measurement.,” JAMA, vol. 
307, no. 20, pp. 2155–6, May 2012. 
[13] A. Gawande, “Complications: A surgeon’s notes on an imperfect science,” 2010. 
[14] K. Walshe, “Adverse events in health care: issues in measurement,” Qual. Heal. Care, 
2000. 
[15] R. M. Wachter and P. J. Pronovost, “Balancing ‘No Blame’ with Accountability in 
Patient Safety,” N. Engl. J. Med., vol. 361, no. 14, pp. 1401–1406, Oct. 2009. 
[16] A. S. Frankel, M. W. Leonard, and C. R. Denham, “Fair and just culture, team 
behavior, and leadership engagement: The tools to achieve high reliability,” Health 
Services Research, vol. 41, no. 4 II. pp. 1690–1709, 2006. 
[17] R. M. Wachter, Understanding patient safety. McGraw Hill Medical, 2012. 
[18] E. Thomas, D. Studdert, H. Burstin, and E. Orav, “Incidence and types of adverse 
events and negligent care in Utah and Colorado,” Med. Care, 2000. 
[19] E. Deilkås, “Gjennomføring av journalundersøkelse med Global Trigger Tool (GTT) i 
den norske pasientsikkerhetskampanjen,” 2011. 
[20] “Mener 200 sykehus-dødsfall kunne vært unngått - Forskning - Dagens Medisin.” 
[Online]. Available: https://www.dagensmedisin.no/artikler/2014/10/09/-ikke-4500-
men-200-sykehus-dodsfall-kunne-vart-unngatt/. [Accessed: 22-Nov-2018]. 
[21] “Lov om erstatning ved pasientskader mv. (pasientskadeloven) - Lovdata.” [Online]. 
Available: https://lovdata.no/dokument/NL/lov/2001-06-15-53. [Accessed: 22-Nov-
2018]. 
[22] T. A. Brennan et al., “Incidence of adverse events and negligence in hospitalized 








[23] E. J. Thomas and L. A. Petersen, “Measuring errors and adverse events in health care,” 
J. Gen. Intern. Med., vol. 18, pp. 61–67, 2003. 
[24] R. Harrison et al., “The missing evidence: a systematic review of patients’ experiences 
of adverse events in health care,” Int. J. Qual. Heal. Care, vol. 27, no. 6, pp. 424–442, 
Dec. 2015. 
[25] S. Lang, M. V. Garrido, and C. Heintze, “Patients’ views of adverse events in primary 
and ambulatory care: A systematic review to assess methods and the content of what 
patients consider to be adverse events,” BMC Fam. Pract., vol. 17, no. 1, 2016. 
[26] S. N. Weingart et al., “What can hospitalized patients tell us about adverse events? 
Learning from patient-reported incidents.,” J. Gen. Intern. Med., vol. 20, no. 9, pp. 
830–6, Sep. 2005. 
[27] J. S. Weissman et al., “Comparing patient-reported hospital adverse events with 
medical record review: do patients know something that hospitals do not?,” Ann. 
Intern. Med., vol. 149, no. 2, pp. 100–8, Jul. 2008. 
[28] J. K. Ward and G. Armitage, “Can patients report patient safety incidents in a hospital 
setting? A systematic review,” BMJ Qual. Saf., vol. 21, no. 8, pp. 685–699, 2012. 
[29] O. Bjertnaes, E. T. Deilkås, K. E. Skudal, H. H. Iversen, and A. M. Bjerkan, “The 
association between patient-reported incidents in hospitals and estimated rates of 
patient harm.,” Int. J. Qual. Health Care, p. mzu087-, Nov. 2014. 
[30] B. Röhrig, J.-B. du Prel, and M. Blettner, “Study design in medical research: part 2 of a 
series on the evaluation of scientific publications.,” Dtsch. Arztebl. Int., vol. 106, no. 
11, pp. 184–9, Mar. 2009. 
[31] L. B. Mokkink et al., “The COSMIN checklist for assessing the methodological quality 
of studies on measurement properties of health status measurement instruments: an 
international Delphi study.,” Qual. Life Res., vol. 19, no. 4, pp. 539–49, May 2010. 
[32] J. Sim and C. C. Wright, “The Kappa Statistic in Reliability Studies: Use, 







268, Mar. 2005. 
[33] L. J. Cronbach, “Coefficient alpha and the internal structure of tests,” Psychometrika, 
vol. 16, pp. 297–334, 1951. 
[34] G. Winter and T. Q. Report, “A Comparative Discussion of the Notion of ‘Validity’ in 
Qualitative and Quantitative Research.pdf,” Qual. Rep., vol. 4, pp. 1–12, 2000. 
[35] R. D. Moen, T. W. Nolan, and L. P. Provost, Quality improvement through planned 
experimentation. McGraw-Hill Professional, 2012. 
[36] A. H. Pripp, “Validitet,” Tidsskr Nor Legeforen 2018 doi 10.4045/tidsskr.18.0398. 
[37] R. Fletcher, S. Fletcher, and G. Fletcher, “Clinical epidemiology: the essentials,” 2012. 
[38] M. Hanskamp-Sebregts, M. Zegers, C. Vincent, P. J. van Gurp, H. C. W. de Vet, and 
H. Wollersheim, “Measurement of patient safety: a systematic review of the reliability 
and validity of adverse event detection with record review.,” BMJ Open, vol. 6, no. 8, 
p. e011078, Aug. 2016. 
[39] M. Venditti, M. LA, S. Corrao, G. Licata, and P. Serra, “Outcomes of Patients 
Hospitalized With Community-Acquired, Health Care–Associated, and Hospital-
Acquired Pneumonia,” Ann. Intern. Med., vol. 150, no. 1, p. 19, Jan. 2009. 
[40] S. S. Magill et al., “Multistate Point-Prevalence Survey of Health Care–Associated 
Infections,” N. Engl. J. Med., vol. 370, no. 13, pp. 1198–1208, Mar. 2014. 
[41] “Sykehus: Infeksjoner og bruk av antibiotika høsten 2016 - FHI.” [Online]. Available: 
https://fhi.no/hn/helseregistre-og-registre/nois/resultater/resultater-sykehus/. [Accessed: 
10-Mar-2017]. 
[42] “World Alliance for Patient Safety: Forward program,” 2006. 
[43] “Summary of the evidence on patient safety: implications for research,” 2008. 
[44] N. Kucher et al., “Electronic Alerts to Prevent Venous Thromboembolism among 
Hospitalized Patients,” N. Engl. J. Med., vol. 352, no. 10, pp. 969–977, Mar. 2005. 
[45] J. A. Heit, F. A. Spencer, and R. H. White, “The epidemiology of venous 







[46] M. R. Kwaan, D. M. Studdert, M. J. Zinner, and A. A. Gawande, “Incidence, patterns, 
and prevention of wrong-site surgery.,” Arch. Surg., vol. 141, no. 4, pp. 353-7; 
discussion 357-8, 2006. 
[47] P. J. Pronovost, I. Joint Commission Resources, and Joint Commission International., 
Safe surgery guide. Joint Commission Resources, 2010. 
[48] “Avisa Nordland - Tragediene i Bodø har ført til stort medisinsk funn: - Dette var ingen 




[49] M. November  Chie, L.,Weingart S.N., “Physician-Reported Adverse Events and 
Medical Errors in Obstetrics and Gynecology,” 2008. 
[50] S. Andreasen, B. Backe, R. G. Jørstad, and P. Øian, “A nationwide descriptive study of 
obstetric claims for compensation in Norway,” Acta Obstet. Gynecol. Scand., vol. 91, 
no. 10, pp. 1191–1195, Oct. 2012. 
[51] D. C. Classen, “Adverse Drug Events in Hospitalized Patients<subtitle>Excess Length 
of Stay, Extra Costs, and Attributable Mortality</subtitle>,” JAMA J. Am. Med. Assoc., 
vol. 277, no. 4, p. 301, 1997. 
[52] S. Andreasen, B. Backe, S. Lydersen, K. Øvrebø, and P. Øian, “The consistency of 
experts’ evaluation of obstetric claims for compensation,” BJOG An Int. J. Obstet. 
Gynaecol., vol. 122, no. 7, pp. 948–953, Jun. 2015. 
[53] “California Medical Association. Report on the medical insurance feasibility study. 
San Francisco: Sutter, 1977.,” 1977. 
[54] H. H. Hiatt et al., “A Study of Medical Injury and Medical Malpractice,” N. Engl. J. 
Med., vol. 321, no. 7, pp. 480–484, Aug. 1989. 
[55] L. Leape and T. Brennan, “THE NATURE OF ADVERSE EVENTS IN 
HOSPITALIZED PATIENTS Results of the Harvard Medical Practice Study II,” N. 







[56] W. C. Richardson et al., To Err is Human: Building A Safer Health System - Institute 
of Medicine. 2000. 
[57] G. R. Baker, “HARVARD MEDICAL PRACTICE STUDY,” Qual. Saf. Heal. Care, 
vol. 13, no. 2, pp. 151–152, Apr. 2004. 
[58] A. Gawande, E. Thomas, M. Zinner, and T. Brennan, “The incidence and nature of 
surgical adverse events in Colorado and Utah in 1992,” Surgery, 1999. 
[59] T. Schiøler, H. Lipczak, and B. Pedersen, “Incidence of adverse events in hospitals. A 
retrospective study of medical records,” Ugeskr., 2001. 
[60] G. Baker, P. Norton, and V. Flintoft, “The Canadian Adverse Events Study: the 
incidence of adverse events among hospital patients in Canada,” Can. Med.  …, 2004. 
[61] C. Vincent, G. Neale, and M. Woloshynowych, “Adverse events in British hospitals: 
preliminary retrospective record review.,” BMJ, vol. 322, no. 7285, pp. 517–9, Mar. 
2001. 
[62] P. Davis, R. Lay-Yee, R. Briant, and W. Ali, “Adverse events in New Zealand public 
hospitals I: occurrence and impact,” 2002. 
[63] J. James, “A new, evidence-based estimate of patient harms associated with hospital 
care,” J. Patient Saf., 2013. 
[64] A. K. Jha, I. Larizgoitia, C. Audera-Lopez, N. Prasopa-Plaizier, H. Waters, and D. W. 
Bates, “The global burden of unsafe medical care: analytic modelling of observational 
studies,” BMJ Qual. Saf., vol. 22, no. 10, pp. 809–815, Oct. 2013. 
[65] “Pasientskader i Norge 2015 målt med Global Trigger Tool - Google-søk,” 2016. 
[66] E. T. Deilkås et al., “Exploring similarities and differences in hospital adverse event 
rates between Norway and Sweden using Global Trigger Tool,” BMJ Open, vol. 7, no. 
3, p. e012492, Mar. 2017. 
[67] K. G. Shojania and E. J. Thomas, “Trends in adverse events over time: why are we not 
improving?,” BMJ Qual. Saf., vol. 22, no. 4, pp. 273–277, Mar. 2013. 







Sharek, “Temporal trends in rates of patient harm resulting from medical care.,” N. 
Engl. J. Med., vol. 363, no. 22, pp. 2124–2134, 2010. 
[69] I. Christiaans-Dingelhoff, M. Smits, L. Zwaan, S. Lubberding, G. Van Der Wal, and C. 
Wagner, “To what extent are adverse events found in patient records reported by 
patients and healthcare professionals via complaints, claims and incident reports?,” 
BMC Health Serv. Res., vol. 11, 2011. 
[70] H. Jick, “Drugs — Remarkably Nontoxic,” N. Engl. J. Med., vol. 291, no. 16, pp. 824–
828, Oct. 1974. 
[71] D. C. Classen, S. L. Pestotnik, R. S. Evans, and J. P. Burke, “Description of a 
computerized adverse drug event monitor using a hospital information system.,” Hosp. 
Pharm., vol. 27, pp. 774, 776–779, 783, 1992. 
[72] J. D. Rozich, C. R. Haraden, and R. K. Resar, “Adverse drug event trigger tool: a 
practical methodology for measuring medication related harm.,” Qual. Saf. Health 
Care, vol. 12, no. 3, pp. 194–200, 2003. 
[73] G. S. Takata, W. Mason, C. Taketomo, T. Logsdon, and P. J. Sharek, “Development, 
testing, and findings of a pediatric-focused trigger tool to identify medication-related 
harm in US children’s hospitals.,” Pediatrics, vol. 121, pp. e927–e935, 2008. 
[74] D. C. Classen, R. C. Lloyd, L. Provost, F. a. Griffin, and R. Resar, “Development and 
Evaluation of the Institute for Healthcare Improvement Global Trigger Tool,” J. 
Patient Saf., vol. 4, no. 3, pp. 169–177, Sep. 2008. 
[75] D. a Kennerly, M. Saldaña, R. Kudyakov, B. da Graca, D. Nicewander, and J. 
Compton, “Description and evaluation of adaptations to the global trigger tool to 
enhance value to adverse event reduction efforts.,” J. Patient Saf., vol. 9, no. 2, pp. 87–
95, Jun. 2013. 
[76] C. von Plessen, A. M. Kodal, and J. Anhøj, “Experiences with global trigger tool 
reviews in five Danish hospitals: an implementation study.,” BMJ Open, vol. 2, no. 5, 
pp. 1–8, Jan. 2012. 







public hospitals : principal findings from a national survey,” 2001. 
[78] E. Deilkås, G. Bukholm, J. Lindstrøm, and M. Haugen, “Monitoring adverse events in 
Norwegian hospitals from 2010 to 2013,” BMJ Open, 2015. 
[79] S. C. Hartwig, S. D. Denger, and P. J. Schneider, “Severity-indexed, incident report-
based medication error-reporting program.,” Am. J. Hosp. Pharm., vol. 48, pp. 2611–
2616, 1991. 
[80] R. J. Baines, M. Langelaan, M. C. de Bruijne, and C. Wagner, “Is researching adverse 
events in hospital deaths a good way to describe patient safety in hospitals: a 
retrospective patient record review study.,” BMJ Open, vol. 5, no. 7, p. e007380, Jan. 
2015. 
[81] J. C. Benneyan, R. C. Lloyd, and P. E. Plsek, “Statistical process control as a tool for 
research and healthcare improvement.,” Qual. Saf. Health Care, vol. 12, no. 6, pp. 
458–64, Dec. 2003. 
[82] J. C. Benneyan, R. C. Lloyd, and P. E. Plsek, “Statistical process control as a tool for 
research and healthcare improvement.,” Qual. Saf. Health Care, vol. 12, pp. 458–464, 
2003. 
[83] “COSMIN checklist.” [Online]. Available: www.cosmin.nl. 
[84] K. Schildmeijer, L. Nilsson, J. Perk, K. Arestedt, and G. Nilsson, “Strengths and 
weaknesses of working with the Global Trigger Tool method for retrospective record 
review: focus group interviews with team members.,” BMJ Open, vol. 3, p. e003131, 
2013. 
[85] D. C. Classen et al., “Measuring Patient Safety: The Medicare Patient Safety 
Monitoring System (Past, Present, and Future).,” J. Patient Saf., 2016. 
[86] J. Garrett, R. Paul, and C. Sammer, “Developing and Implementing a Standardized 
Process for Global Trigger Tool Application Across a Large Health System,” … J. 
Qual. …, vol. 39, no. 7, 2013. 
[87] J. M. Naessens, T. J. O’Byrne, M. G. Johnson, M. B. Vansuch, C. M. McGlone, and J. 







trigger performance of the Global Trigger Tool.,” Int. J. Qual. Health Care, vol. 22, 
no. 4, pp. 266–74, Aug. 2010. 
[88] K. Mevik, F. Griffin, T. Hansen, E. Deilkås, and B. Vonen, “Does increasing the size 
of bi-weekly samples of records influence results when using the Global Trigger Tool? 
An observational study of retrospective record reviews,” BMJ Open, 2016. 
[89] R. Zimmerman et al., “Aiming for zero preventable deaths: using death review to 
improve care and reduce harm.,” Healthc. Q., vol. 13 Spec No, pp. 81–7, Jan. 2010. 
[90] E. J. Thomas, S. R. Lipsitz, D. M. Studdert, and T. A. Brennan, “The reliability of 
medical record review for estimating adverse event rates,” Ann Intern Med, vol. 136, 
no. 11, pp. 812–816, 2002. 
[91] P. D. Hibbert et al., “The application of the Global Trigger Tool: a systematic review,” 
Int. J. Qual. Heal. Care, vol. 28, no. 6, pp. 640–649, Sep. 2016. 
[92] A. J. Forster, J. Andrade, and C. Van Walraven, “Validation of a discharge summary 
term search method to detect adverse events,” Journal of the American Medical 
Informatics Association, vol. 12, no. 2. pp. 200–206, 2005. 
[93] P. M. Kilbridge et al., “Computerized Surveillance for Adverse Drug Events in a 
Pediatric Hospital,” J. Am. Med. Informatics Assoc., vol. 16, no. 5, pp. 607–612, 2009. 
[94] D. C. Stockwell et al., “Development of an Electronic Pediatric All-Cause Harm 
Measurement Tool Using a Modified Delphi Method.,” J. Patient Saf., vol. 00, no. 00, 
pp. 1–10, Aug. 2014. 
[95] H. Rognebakke, “Kvalitetssikring av rapport om GTT-gjennomgang i norske sykehus,” 
Oslo, 2011. 
[96] E. von Elm et al., “The Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies,” 
PLoS Med., vol. 4, no. 10, p. e296, Oct. 2007. 
[97] J. R. Landis and G. G. Koch, “The measurement of observer agreement for categorical 
data.,” Biometrics, vol. 33, no. 1, pp. 159–74, Mar. 1977. 







no. 15, pp. 1993–1994, Mar. 2000. 
[99] M. Fiszman, W. W. Chapman, D. Aronsky, R. S. Evans, and P. J. Haug, “Automatic 
Detection of Acute Bacterial Pneumonia from Chest X-ray Reports,” J. Am. Med. 
Informatics Assoc., vol. 7, no. 6, pp. 593–604, Nov. 2000. 
[100] R. G. Newcombe, “Two-sided confidence intervals for the single proportion: 
Comparison of seven methods,” Stat. Med., vol. 17, no. 8, pp. 857–872, 1998. 
[101] D. W. Baker and S. D. Persell, “Criteria for Waiver of Informed Consent for Quality 
Improvement Research,” JAMA Intern. Med., vol. 175, no. 1, p. 142, Jan. 2015. 
[102] Council for International Organizations of Medical Sciences, “International ethical 
guidelines for biomedical research involving human subjects.,” 2002. 
[103] World Health Organization, “Ethical issues in Patient Safety Research interpreting 
existing guidance,” 2013. 
[104] L. Harrington, “Quality improvement, research, and the institutional review board,” J. 
Healthc. Qual., 2007. 
[105] R. A. Hayward, M. Heisler, J. Adams, R. A. Dudley, and T. P. Hofer, “Overestimating 
outcome rates: Statistical estimation when reliability is suboptimal,” Health Serv. Res., 
vol. 42, pp. 1718–1738, 2007. 
[106] P. Michel, J. L. Quenon, A. M. de Sarasqueta, and O. Scemama, “Comparison of three 
methods for estimating rates of adverse events and rates of preventable adverse events 
in acute care hospitals.,” BMJ, vol. 328, no. 7433, p. 199, Jan. 2004. 
[107] C. Sammer et al., “Developing and Evaluating an Automated All-Cause Harm Trigger 
System,” Jt. Comm. J. Qual. Patient Saf., vol. 0, no. 0, Feb. 2017. 
[108] H. Lau and K. C. Litman, “Saving lives by studying deaths: Using standardized 
mortality reviews to improve inpatient safety,” Joint Commission Journal on Quality 
and Patient Safety, vol. 37, no. 9. pp. 400–408, 2011. 
[109] V. B. Haukland Ellinor, Mevik Kjersti, von Plessen Chrisitan, Nieder Carsten, “The 







[110] P. J. Sharek et al., “Performance characteristics of a methodology to quantify adverse 
events over time in hospitalized patients.,” Health Serv. Res., vol. 46, no. 2, pp. 654–
78, Apr. 2011. 
[111] V. Good and M. Saldana, “Large-scale deployment of the Global Trigger Tool across a 
large hospital system: refinements for the characterisation of adverse events to support 
patient safety,” BMJ Qual.  …, 2011. 
[112] C. R. Blyth, “On Simpson’s Paradox and the Sure-Thing Principle,” J. Am. Stat. 
Assoc., vol. 67, pp. 364–366, 1972. 
[113] M. Zegers, M. C. de Bruijne, C. Wagner, P. P. Groenewegen, G. van der Wal, and H. 
C. W. de Vet, “The inter-rater agreement of retrospective assessments of adverse 
events does not improve with two reviewers per patient record.,” J. Clin. Epidemiol., 
vol. 63, no. 1, pp. 94–102, Jan. 2010. 
[114] J. Faber and L. M. Fonseca, “How sample size influences research outcomes.,” Dental 
Press J. Orthod., vol. 19, no. 4, pp. 27–9, 2014. 
[115] K. J. O’Leary et al., “Comparison of traditional trigger tool to data warehouse based 
screening for identifying hospital adverse events.,” BMJ Qual. Saf., vol. 22, no. 2, pp. 
130–8, Feb. 2013. 
[116] J. Ferranti et al., “A Multifaceted Approach to Safety,” J. Patient Saf., vol. 4, no. 3, pp. 
184–190, Sep. 2008. 
[117] D. C. Classen, “Computerized surveillance of adverse drug events in hospital patients,” 
Qual. Saf. Heal. Care, vol. 14, no. 3, pp. 221–226, Jun. 2005. 
[118] A. K. Jha et al., “Identifying Adverse Drug Events,” J. Am. Med. Informatics Assoc., 
vol. 5, no. 3, pp. 305–314, 1998. 
[119] D. W. Bates, R. S. Evans, H. Murff, P. D. Stetson, L. Pizziferri, and G. Hripcsak, 
“Detecting adverse events using information technology.,” J. Am. Med. Inform. Assoc., 
vol. 10, no. 2, pp. 115–128, 2003. 
[120] D. C. Stockwell, E. Kirkendall, S. E. Muething, E. Kloppenborg, H. Vinodrao, and B. 







identification, classification, and corrective actions across academic pediatric 
institutions,” J Patient Saf, vol. 9, no. 4, pp. 203–210, 2013. 
[121] V. Lemon and D. C. Stockwell, “Automated Detection of Adverse Events in Children,” 
Pediatric Clinics of North America, vol. 59, no. 6. pp. 1269–1278, 2012. 
[122] H. J. Murff, V. L. Patel, G. Hripcsak, and D. W. Bates, “Detecting adverse events for 
patient safety research: a review of current methodologies,” J. Biomed. Inform., vol. 
36, no. 1–2, pp. 131–143, Feb. 2003. 
[123] G. B. Melton and G. Hripcsak, “Automated detection of adverse events using natural 
language processing of discharge summaries.,” J. Am. Med. Inform. Assoc., vol. 12, no. 
4, pp. 448–57, Jan. 2005. 
[124] C. M. Rochefort et al., “Accuracy and generalizability of using automated methods for 
identifying adverse events from electronic health record data: a validation study 
protocol,” BMC Health Serv. Res., vol. 17, no. 1, p. 147, Dec. 2017. 
[125] M. Benson, A. Junger, A. Michel, and G. Sciuk, “Comparison of manual and 
automated documentation of adverse events with an Anesthesia Information 
Management System (AIMS).,” Stud. Heal., 1999. 
[126] L. I. Iezzoni et al., “Identifying complications of care using administrative data.,” Med. 
Care, vol. 32, no. 7, pp. 700–15, Jul. 1994. 
[127] H. J. Murff, A. J. Forster, J. F. Peterson, J. M. Fiskio, H. L. Heiman, and D. W. Bates, 
“Electronically screening discharge summaries for adverse medical events,” J. Am. 
Med. Informatics Assoc., vol. 10, pp. 339–350, 2003. 
[128] J. F. E. Penz, A. B. Wilcox, and J. F. Hurdle, “Automated identification of adverse 
events related to central venous catheters.,” J. Biomed. Inform., vol. 40, no. 2, pp. 174–
82, Apr. 2007. 
[129] D. W. Bates, R. S. Evans, H. Murff, P. D. Stetson, L. Pizziferri, and G. Hripcsak, 
“Detecting Adverse Events Using Information Technology,” J. Am. Med. Informatics 
Assoc., vol. 10, no. 2, pp. 115–128, Mar. 2003. 







method of adverse event detection can accurately identify venous thromboembolisms 
(VTEs) from narrative electronic health record data,” J. Am. Med. Informatics Assoc., 
vol. 45, no. (43), pp. 992–8, Oct. 2014. 
[131] B. Hazlehurst, H. R. Frost, D. F. Sittig, and V. J. Stevens, “MediClass: A system for 
detecting and classifying encounter-based clinical events in any electronic medical 
record.,” J. Am. Med. Inform. Assoc., vol. 12, no. 5, pp. 517–29, Jan. 2005. 
[132] B. Hazlehurst, A. Naleway, and J. Mullooly, “Detecting possible vaccine adverse 
events in clinical notes of the electronic medical record,” Vaccine, vol. 27, no. 14, pp. 
2077–2083, 2009. 
[133] C. J. McDonald, “The barriers to electronic medical record systems and how to 
overcome them,” J Am Med Inf. Assoc, vol. 4, no. 3, pp. 213–221, 1997. 
[134] B. Kaplan, “Reducing barriers to physician data entry for computer-based patient 
records,” Top. Health Inf. Manage., vol. 15, no. 1, pp. 24–34, 1994. 
[135] G. B. Melton and G. Hripcsak, “Automated detection of adverse events using natural 
language processing of discharge summaries.,” J. Am. Med. Inform. Assoc., vol. 12, no. 
4, pp. 448–57, Jan. 2005. 
[136] D. W. Bates, A. C. O’Neil, L. A. Petersen, T. H. Lee, and T. A. Brennan, “Evaluation 
of screening criteria for adverse events in medical patients.,” Med. Care, vol. 33, no. 5, 
pp. 452–62, May 1995. 
[137] Z. Obermeyer and E. J. Emanuel, “Predicting the Future - Big Data, Machine Learning, 
and Clinical Medicine.,” N. Engl. J. Med., vol. 375, no. 13, pp. 1216–9, Sep. 2016. 
[138] F. Cabitza, R. Rasoini, and G. F. Gensini, “Unintended Consequences of Machine 
Learning in Medicine,” JAMA, vol. 318, no. 6, p. 517, Aug. 2017. 
[139] A. K. Jha et al., “Identifying adverse drug events: Development of a computer-based 
monitor and comparison with chart review and stimulated voluntary report,” J. Am. 
Med. Informatics Assoc., vol. 5, no. 3, pp. 305–314, May 1998. 
[140] A. Donabedian, “Evaluating the quality of medical care. 1966.,” Milbank Q., vol. 83, 








Norwegian GTT Trigger sheet 
Norwegian GTT Categories of harm and severity 
Approval from the Regional Committee for Medical and Health and Research Ethics 
Letter from the Norwegian Social Science Data Service 
Approval from the Data Protection Office at the Nordland Hospital trust 
Trial invitation letter 








Trigger Care module Triggers  Medication Module Triggers 
C1 Transfusion or use of blood products M1 Clostridium difficile positive stool 
C2 Code/arrest/rapid response team M3 INR greater than 6 
C3 Acute dialysis M4 Glucose less than 2.8 mmol/l 
C4 Positive blood culture M5 Rising BUN or serum creatinine greater than 2 times baseline 
C5 X-ray or Doppler studies for emboli or DVT M6* Vitamin K administration 
C6 Decrease of greater than 25% in hemoglobin or hematocrit M7* Benadryl (Diphenhydramine) use 
C7 Patient fall M8* Romazicon (Flumazenil) use 
C8 Pressure ulcers M9* Naloxone (Narcan) use 
C9 Readmission within 30 days M10* Anti-emetic use 
C10* Restraint use M11* Over-sedation/hypotension 
C11 Healthcare-associated infection M12* Abrupt medication stop 
C12 In-hospital stroke M13* Other 
C13 Transfer to higher level of care  Intensive Care Module Triggers 
C14 Any procedure complication I1 Pneumonia onset 
C15* Other  I2 Readmission to intensive care 
 Surgical Module Triggers I3 In-unit procedure 
S1 Return to surgery I4 Intubation/reintubation 
S2 Change in procedure  Perinatal Module Triggers 
S3 Admission to intensive care post-op P1* Terbutaline use 
S4 Intubation/reintubation/BiPap in PACU P2 3rd- or 4th-degree lacerations 
S5* X-ray intra-op or in PACU P3 Platelet count less than 50,000 
S6 Intra-op or post-op death P4 Estimated blood loss > 500 ml (vaginal) or > 1,000 ml (C-section) 
S7 Mechanical ventilation greater than 24 hours post-op P5 Specialty consult 
S8* Intra-op epinephrine, norepinephrine, naloxone, or romazicon P6* Oxytocic agents 
S9 Post-op troponin level greater than 40 ng/l P7 Instrumented delivery 
S10 Injury, repair, or removal of organ because of accidental injury P8 General anesthesia 
S11 Change in anesthesia procedure P9 Apcar score <7 after 5 minute 
S12 Insertion of artery catheter or central venous catheter P10 Induced labour 
S13 Surgery more than 6 hours  Emergency Department Module Triggers 
S14* Any operative complication E1 Readmission to ED within 48 hours 











Severity of adverse event 
 
Category E: Temporary harm to the patient and required intervention  
Category F: Temporary harm to the patient and required initial or prolonged hospitalisation  
Category G: Permanent patient harm  
Category H: Intervention required to sustain life  
Category I: Patient death 
 
Type of adverse event 
 
 
Hospital acquired infections 
Urinary tract infection 
CVC infection 
Ventilator associated pneumonia 
Other infection 
Lower respiratory infection 
Surgical complications 
Infection after surgery 
Respiratory complications after 
surgery 
Return to surgery 
Injury, repair or removal of organ 
Occurrence of any operative 
complication 




Bleeding after surgery 






Medical technical harm 
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2012/1691 Validering av Global Trigger Tool som målemetode for kartlegging av pasientskader 
 Nordlandssykehuset HF Forskningsansvarlig:
 Barthold Vonen Prosjektleder:
Vi viser til søknad om forhåndsgodkjenning av ovennevnte forskningsprosjekt. Søknaden ble behandlet av
Regional komité for medisinsk og helsefaglig forskningsetikk (REK vest) i møtet 18.10.2012. Vurderingen
er gjort med hjemmel i helseforskningsloven § 10, jf. forskningsetikklovens § 4.
Prosjektomtale
Global Trigger Tool (GTT) er en metode som alle helseforetak er pålagt å bruke for å kartlegge
pasientskader i egen virksomhet. I dette prosjektet ønskes det å undersøke om GTT metoden er et robust og
sensitivt verktøy brukt på dagens elektroniske pasientjournaler. Studien innebærer for det første to
delstudier på selve GTT-metoden hvor det skal benyttes registerdata. I en tredje delstudie skal det gjøres
journalgjennomganger fra minimum 240 tilfeldig utplukkede sykehusopphold. Her skal en bruke GTT
metoden for å kartlegge evt pasientskader/uønskede hendelser. Det skal hentes inn samtykke for




Det hersker stor usikkerhet omkring spørsmålet om både omfang og alvorlighetsgrad av pasientskader ved
norske sykehus. Både for pasientenes egen del og for samfunnets evne til å foreta nødvendige prioriteringer
innenfor helsevesenet, er det svært viktig at det finnes gode og sammenlignbare oversikter over
pasientskadene. Som politisk tema er dette også høyaktuelt. Derfor er dette en søknad REK Vest mener er
svært viktig. Komiteen mener også at protokollen er egnet til å besvare de spørsmål en reiser. 
Rekruttering/samtykke
Datamateriale hentes fra to kilder:
1.
Registerdata: Data fra GTT ved 7 enheter ved Norlandssykehuset i perioden 2010. Det gjennomgås årlig ca
1680 pasientopphold.  Disse opplysningene skal anonymiseres og overføres til en database. Det søkes om
fritak fra samtykkekravet for disse pasientene. Dette er begrunnet med at dataene skal konverteres til en
forskningsdatabase hvor koblingsnøkkel er fjernet. Videre opplyses det at arbeidet med å etablere
forskningsdatabasen gjøres av personell utenfor selve forskningsprosjektet og i regi av forskningsansvarlig. 
Adgang til bruk av helseopplysninger som er innsamlet i helsetjenesten til forskning er regulert i
helseforskningslovens § 35. Vilkårene for å kunne tillate dette uten innhenting av samtykke, er at
forskningen skal være av vesentlig interesse for samfunnet og at hensynet til deltakernes velferd og
integritet er ivaretatt. 
REK Vest mener at samfunnsnytten er godt dokumentert. Slik en har lagt opp anonymiseringsprosessen,
mener komiteen at hensynet til deltakernes velferd og integritet også er godt ivaretatt. REK Vest vil
godkjenne søknaden på dette punkt.
2.
Nye helseopplysninger: Journalgjennomgang av 240 tilfeldig utplukkede sykehusopphold ved
Nordlandssykehuset.  Denne delen er samtykkebasert. 
Det vedlagte utkast til forespørsel er imidlertid av dårlig kvalitet. En må bestrebe seg på å benytte et mer
allment tilgjengelig språk hvor det er på en enklere måte beskrives hva deltakelse innebærer. REK Vest
ønsker å få det reviderte skrivet tilsendt, før endelig vedtak fattes.
Informasjonssikkerhet
Det opplyses at koblingsnøkkel oppbevares ved egen institusjon og at personidentifiserbare opplysninger
oppbevares på institusjonens server.  REK Vest forutsetter at koblingsnøkkel og personidentifiserbare
opplysninger oppbevares separat. 
Vedtak 
Søken utsettes i påvente av tilbakemelding på ovennevnte merknad.
 
Vennligst benytt skjema for tilbakemelding som sendes inn via saksportalen til REK 
.http://helseforskning.etikkom.no
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Vi viser til tilbakemelding om forhåndsgodkjenning av ovennevnte forskningsprosjekt. Tilbakemeldingen ble
behandlet av leder av REK Vest på fullmakt. Vurderingen er gjort med hjemmel i helseforskningsloven § 10,
jf. forskningsetikkloven § 4.
Vurdering:
Tilbakemelding
REK Vest krevde at informasjonsskrivet ble forfattet i et mer allment tilgjengelig språk. Et revidert skriv
foreligger nå.
Ny vurdering i REK
REK Vest finner det nye informasjonsskrivet tilfredsstillende og har ingen ytterligere innvendinger til
prosjektsøknad.
Vedtak:
REK Vest godkjenner prosjektet i samsvar med søknad og tilbakemelding.
Sluttmelding og søknad om prosjektendring
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Vi viser til søknad om prosjektendring datert 05.02.2018 for ovennevnte forskningsprosjekt. Søknaden er
behandlet av leder for REK vest på fullmakt, med hjemmel i helseforskningsloven § 11.
Vurdering
REK vest omfatter det slik at prosjektendringen innebærer ikke innsamling av nye data. Det er testing av
validiteten til GTT som er formålet med prosjektendringen. Videre søker prosjektlederen om forlengelse av
prosjektet til 05.07.2018.
Vurdering:
REK vest merker seg at prosjektet er gått ut på dato 31.08.2017. Vi gjør oppmerksom på at søknad om
forlengelse av prosjektet skal sendes inn før prosjektsluttdato.
Vedtak
REK vest godkjenner prosjektendringen i samsvar med forelagt søknad. 
Klageadgang
Du kan klage på komiteens vedtak, jf. helseforskningsloven § 10 og forvaltningsloven § 28 flg. Klagen
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ANBEFALING AV BEHANDLING AV PERSONOPPLYSNINGER 
 
 
Viser til melding om behandling av personopplysninger, mottatt 21.06. 
 
Tittel: Validering av GTT som målemetode for kartlegging av pasientskader 
 
Formål med prosjektet:  Å teste verktøyet GTT som brukes til kartlegge pasientskader. Metoden 
går ut på å screene pasientjournaler etter utvalgte triggere (lab verdi, fall, infeksjoner som kan 
oppstå i pasientforløpet) som kan indikere at en pasientskade har skjedd. Målet med studien er å 
finne den optimale utvalgsstørrelsen som trengs for å estimere antall skader, om utskiftning av de 
som screener påvirker resultatet og om ett automatisk verktøy kan erstatte den manuelle 
granskningen 
 
Tidspunkt for prosjektet (til/fra): 01.01.2013 – 31.12.17. 
 
Forskningsprosjektet krever forhåndsgodkjenning av REK. Personvernombudets (PVO) rolle er å ha 
oversikt over forskningsprosjekter samt se til at informasjonssikkerheten og personvernet blir 
ivaretatt.  
 
Det forutsettes at prosjektet gjennomføres i tråd med de opplysningene som er gitt i selve 
meldingen samt i øvrig korrespondanse og samtaler. Videre forutsettes det at bestemmelsene i lov 
om behandling av personopplysninger og lov om helseregistre og behandling av helseopplysninger 
med forskrifter følges. Prosjektet må videre gjennomføres i henhold til annet relevant regelvert, 
herunder de alminnelige regler om taushetsplikt.  
 
 Dersom registeret skal brukes til annet formål enn det som er nevnt i meldingen må det 
meldes særskilt i hvert enkelt tilfelle.  
 Dersom prosjektet har varighet på mer enn tre år skal prosjektansvarlig hvert tredje år 
sende bekreftelse til personvernombud på at behandlingen skjer i overensstemmelse med 
søknaden og vilkårene som er nevnt i denne godkjennelsen. 
 Det skal gis tilbakemelding til personvernombudet når registret er slettet. 
 
Med hjemmel i personopplysningslovens forskrift § 7-12 godkjennes det at behandlingen av 
















Vedlegg – forskningsprosjekt 
 
Helseforskningsloven  
§ 10.Søknad om forhåndsgodkjenning 
Søknad om forhåndsgodkjenning av et forskningsprosjekt skal sammen med forskningsprotokollen 
sendes til den regionale komiteen for medisinsk og helsefaglig forskningsetikk. 
Den regionale komiteen for medisinsk og helsefaglig forskningsetikk skal foreta en alminnelig 
forskningsetisk vurdering av prosjektet, og vurdere om prosjektet oppfyller kravene stilt i denne 
loven eller i medhold av denne loven. Den regionale komiteen for medisinsk og helsefaglig 
forskningsetikk kan sette vilkår for godkjenning. 
Vedtak vedrørende forhåndsgodkjenning kan påklages til Den nasjonale forskningsetiske komité for 
medisin og helsefag, jf. lov 30. juni 2006 nr. 56 om behandling av etikk og redelighet i forskning § 4. 
Departementet kan gi forskrifter om krav til søknaden, om saksbehandlingsfrister for den regionale 
komiteen for medisinsk og helsefaglig forskningsetikk, og om de nærmere vilkårene for 
forhåndsgodkjenning 
 
Forskrift om behandling av personopplysninger 
§ 7-12.Personvernombud 
Datatilsynet kan samtykke i at det gjøres unntak fra meldeplikt etter personopplysningsloven § 31 
første ledd, dersom den behandlingsansvarlige utpeker et uavhengig personvernombud som har i 
oppgave å sikre at den behandlingsansvarlige følger personopplysningsloven med forskrift. 
Personvernombudet skal også føre en oversikt over opplysningene som nevnt i 
personopplysningsloven § 32. 
 
Forespørsel om deltakelse i forskningsprosjektet: 
Validering av Global Trigger Tool som målemetode for kartlegging av pasientskader 
 
Bakgrunn og hensikt 
Forskningsprosjektet skal undersøke om en ved bruk av GTT – Global Trigger tool -  kan 
finne og dokumentere uønskede hendelser og skader på pasienter som følge av behandling i 
norske sykehus. Alle norske helseforetak er pålagt å bruke GTT-metoden for å kartlegge 
pasientskader i egen virksomhet. Antall, type og alvorlighet ved pasientskader rapporteres 
regelmessig til et sentralt register og offentliggjøres. I vår studie skal vi undersøke om GTT- 
metoden gir pålitelig data også når det brukes på dagens elektroniske pasientjournaler. For å 
kunne si noe om dette, ønsker vi å analysere data fra 240 pasientopphold ved 
Nordlandssykehuset med tanke på antall, type og alvorlighetsgrad av mulige 
behandlingsrelaterte skader og uønskede hendelser. Vi ber med dette om din tillatelse til å 
bruke journaldata fra opphold ved Nordlandssykehuset i dette arbeidet.  
Hva innebærer studien? 
Studien foregår ved at 240 sykehusopphold ved Nordlandssykehuset HF i perioden 
01.01.2010 – 31.12.2010 trekkes tilfeldig av det totale antallet innleggelser ved sykehuset i 
samme periode. Ditt opphold ved Nordlandssykehuset i perioden (dato fylles inn) er trukket 
ut. Vi ber med dette om din tillatelse til at journaldata fra dette oppholdet kan gjennomgås av 
1 lege og 1 sykepleier fra prosjektgruppa for å finne ut om det inntraff uønskede hendelser og 
om du ble påført skader. Er du pårørende ber vi om at du gir samtykke på vegne av pasienten. 
 
Mulige fordeler og ulemper 
For deg som pasient innebærer studien ingen ulemper eller direkte fordeler. Hvis du 
samtykker til denne undersøkelsen vil helsepersonell som deltar i dette forskningsprosjektet få 
innsyn i din pasientjournal. Finner vi at du har opplevd en alvorlig uønsket hendelse eller blitt 
skadet som følge av behandlingen, vil du bli kontaktet og informert om dette og du vil få 
tilbud om samtale med en av de som har gjennomgått journalen din. Vi vil ikke lete etter 
eventuelle nye lidelser/diagnoser, men kun vurdere om det forelå en pasientskade eller 
uønsket hendelse som følge av behandlingen du mottok i løpet av det aktuelle oppholdet. 
  
Hva skjer med informasjonen om deg?  
Informasjonen som registreres om deg skal kun brukes slik som beskrevet ovenfor. Når alle 
data fra sykehusoppholdet er gjennomgått, blir eventuelle skader eller uønskede hendelser 
registrert og lagret atskilt fra journalen din uten ditt navn, fødselsnummer eller andre direkte 
eller indirekte identifiserbare opplysninger (anonymisert). Det vil heller ikke være mulig å 
identifisere de enkelte deltagere i de publiserte resultatene av studien. Dersom vi senere 
ønsker å bruke de opplysningene vi har samlet inn til et annet forskningsprosjekt, vil du bli 
forespurt og videre bruk forutsetter at du samtykker også til det. 
 
1.1 Personvern 
Opplysninger som ønskes registrert om deg skal hentes fra Nordlandssykehuset elektroniske 
journalsystem. I vår studie skal dette ikke koples til andre lokale/nasjonale registre eller bli 
overlatt til andre forskere. Nordlandssykehuset ved administrerende direktør Paul Martin 
Strand er ansvarlig for håndtering og lagring av data. 
 
1.2 Rett til innsyn og sletting av opplysninger om deg 
Hvis du sier ja til å delta i studien, har du rett til å få innsyn i hvilke opplysninger som er 
registrert om deg. Du har videre rett til å få korrigert eventuelle feil i de opplysningene vi har 
registrert. Dersom du trekker deg fra studien, kan du kreve å få slettet alle innsamlede data, 
med mindre opplysningene allerede er benyttet i analyser eller i vitenskapelige publikasjoner. 
Studien er finansiert gjennom forskningsmidler fra Helse Nord og resultatene fra studien blir 
publisert i nasjonale og internasjonale fagtidsskrifter. 
 
Frivillig deltakelse 
Det er frivillig å delta i studien. Du kan når som helst og uten å oppgi noen grunn trekke ditt 
samtykke til deltagelse uten at dette vil noen konsekvenser for deg i din fremtidige kontakt 
med Nordlandssykehuset. Dersom du ønsker å delta, undertegner du samtykkeerklæringen på 
siste side snarest mulig og returnerer dette i vedlagt konvolutt. Dersom du senere ønsker å 
trekke deg eller har spørsmål til studien, kan du kontakte: 
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Jeg har lest prosjektbeskrivelsen ovenfor og gir samtykke til at journaldata fra min eller en 
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